Author: "Eric Mallet" - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Eric Mallet"' showing total 93 results

Start Over Author "Eric Mallet"

93 results on '"Eric Mallet"'

1. Evaluation of a new, wireless pulse oximetry monitoring system in infants: the BBA bootee.

Author: Yves Rimet, Yves Brusquet, Dominique Ronayette, Christian Dageville, Marc Lubrano, Eric Mallet, Caroline Rambaud, Christian Terlaud, Larissa I. Netchiporouk, David Blanc, Jérôme Silve, Olivier Lerda, Francis Klefstad-Sillonville, and Jean-Luc Weber
Published: 2007
Full Text: View/download PDF

2. Durability of immunogenicity and strain coverage of MenBvac, a meningococcal vaccine based on outer membrane vesicles: Lessons of the Normandy campaign

Author: Ludovic Lemée, Eva Hong, Julien Sevestre, Valérie Delbos, Ala-Eddine Deghmane, François Caron, Eric Mallet, Muhamed-Kheir Taha, Aude Terrade, CHU Rouen, Normandie Université (NU), Université de Rouen Normandie (UNIROUEN), Institut Pasteur [Paris], Department of Statistics [Oxford], University of Oxford [Oxford], This work was supported the Institut Pasteur and Rouen University Hospital. JS receives a fellowship from the Conseil Régional de Haute Normandie. We thank Marie-Noelle Ungeheuer (Institut Pasteur-ICAReB) for supply of human serum samples for complement sources., Institut Pasteur [Paris] (IP), and University of Oxford
Subjects: 0301 basic medicine, Male, persistence of vaccine response, MESH: Secretory Vesicles, Neisseria meningitidis, Serogroup B, medicine.disease_cause, MESH: Meningococcal Infections, MESH: Meningococcal Vaccines, 0302 clinical medicine, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, 030212 general & internal medicine, Strain (chemistry), Immunogenicity, Neisseria meningitidis, MESH: Blood Bactericidal Activity, MESH: Infant, 3. Good health, Vaccination, Titer, Infectious Diseases, Child, Preschool, Molecular Medicine, Female, France, Bacterial outer membrane, Blood Bactericidal Activity, Meningococcal Vaccines, Meningococcal vaccine, Biology, Microbiology, PorA, serum bactericidal activity, 03 medical and health sciences, MESH: Neisseria meningitidis, Serogroup B, medicine, Humans, MESH: Humans, General Veterinary, General Immunology and Microbiology, outbreak, Secretory Vesicles, invasive meningococcal disease, MESH: Child, Preschool, Public Health, Environmental and Occupational Health, Outbreak, Infant, vaccination, Virology, MESH: Male, Meningococcal Infections, MESH: France, 030104 developmental biology, [SDV.IMM.VAC]Life Sciences [q-bio]/Immunology/Vaccinology, Neisseria meningitidis serogroup B, MESH: Female
Abstract: International audience; OBJECTIVES:MenBvac® is an outer membrane vesicle (OMV)-based meningococcal vaccine. From 2006 to 2012, it was used to control a clonal B outbreak in Normandy (France). We aimed to analyse the durability of the response against the epidemic strain and coverage beyond the vaccine strain. These data should help to optimize the use of OMV-containing vaccines, such as the new 4CMenB/Bexsero® recombinant vaccine.METHODS:Serum bactericidal activity (SBA) was measured in two cohorts of children who received their first dose of MenBvac® at 1-5years of age and accepted to provide a blood sample either one or four years after a 2+1+1 schedule. All sera were tested against the outbreak strain. Sera from responder subjects were also tested against 12 additional B or C strains which were chosen to entirely, partially, or not at all match the two variable regions (VR1 and VR2) of the PorA vaccine strain.RESULTS:Only 47.9% and 31.3% of subjects showed an SBA titre consistent with protection one and four years, respectively, after the last boost. Protective SBA titres were observed in all sera against B or C strains that entirely matched P1.7,16, and was high (75-100%) for all but one strain that partially matched VR1 or VR2. Extrapolating our data to the OMV component of 4CMenB/Bexsero® suggests that 14.5% of the current B strains would be covered based on PorA matching to the OMV component of 4CMenB/Bexsero® (regardless of the coverage of the three other vaccine components).CONCLUSIONS:Our data confirm that OMV-based vaccines elicit short-lasting SBA titres and may require repeated booster injections. However, strain coverage may be greater than expected.
Published: 2017
Full Text: View/download PDF

3. Statut en vitamine D des enfants de 6 à 10ans : étude nationale multicentrique chez 326 enfants

Author: Joël Gaudelus, J. Uhlrich, Eric Mallet, Philippe Reinert, J. Cordero, J.P. Basuyau, A. Roden, J. Stagnara, Jacques Benichou, and M. Maurin
Subjects: Gynecology, medicine.medical_specialty, Multicenter study, business.industry, Pediatrics, Perinatology and Child Health, Vitamin D and neurology, Medicine, business
Abstract: Resume Objectif Apprecier le statut en vitamine D des enfants de 6 a 10 ans. Methode L’etude s’est deroulee sur deux hivers d’ensoleillement different dans 20 puis 22 centres. Trois cent enfants âges de 6 a 10 ans devaient etre inclus en fin de periode hivernale et les dosages realises sur reliquat biologique dans un laboratoire centralise. Les seuils actuellement retenus de 25 hydroxyvitamine D (25-OH-D) ont permis de definir les situations de deficit severe ou carence (≤ 25 nmol/L), de deficit (25 100 nmol/L). Un questionnaire standardise a permis de renseigner les informations connexes necessaires et les niveaux d’ensoleillement ont ete connus grâce a Meteo-France. Resultats Un dosage plasmatique de 25-OH-D a pu etre realise chez 326 enfants ; 38 % avaient recu une supplementation vitaminique D depuis la rentree scolaire. On a compte 3,1 % d’enfants en situation de carence, 34,4 % en deficit, 53,1 % en statut satisfaisant et 9,5 % avec une concentration haute sans consequence sur la calcemie et la calciurie. Une difference nord/sud a ete observee. Dans la population non supplementee ( n = 188), 5,3 % etaient carences, 45,2 % en deficit et 48,4 % avaient un taux satisfaisant. Le pourcentage de carence et de deficit etait double l’hiver le moins ensoleille. Dans la population supplementee ( n = 119), aucune carence n’a ete constatee ; 13,4 % des enfants etaient en situation de deficit et 22,7 % avaient une concentration haute sans signe de surcharge. Conclusion Un tiers des enfants presentait une concentration deficitaire en 25-OH-D. Parmi les enfants supplementes, aucun n’etait carence, peu en situation de deficit et aucun signe de surcharge n’a ete note alors que chez les enfants non supplementes la moitie (50,5 %) etait en situation de deficit en fin d’hiver. Ces resultats plaident en faveur d’une supplementation hivernale chez les enfants.
Published: 2014
Full Text: View/download PDF

4. Weakening osteopathies, chronic kidney disease, malabsorption, biological anomalies of calium/phosphorus metabolism: appropriate indications for a reasoned reimbursment of serum vitamin D measurement

Author: Jean-Claude Souberbielle, Claude Laurent Benhamou, Bernard Cortet, Mickael Rousière, Christian Roux, Vered Abitbol, Cédric Annweiler, Maurice Audran, Justine Bacchetta, Pierre Bataille, Olivier Beauchet, Rémi Bardet, Alexandra Benachi, Francis Berenbaum, Hubert Blain, Françoise Borson-Chazot, Véronique Breuil, Karine Briot, Philippe Brunet, Jean-Claude Carel, Philippe Caron, Olivier Chabre, Philippe Chanson, Roland Chapurlat, Pierre Cochat, Régis Coutant, Sophie Christin-Maitre, Martine Cohen-Solal, Christian Combe, Catherine Cormier, Marie Courbebaisse, Grégory Debrus, Brigitte Delemer, Georges Deschenes, Marc Duquenne, Patrice Fardellone, Denis Fouque, Gérard Friedlander, Jean-Bernard Gauvain, Lionel Groussin, Pascal Guggenbuhl, Pascal Houillier, Thierry Hannedouche, William Jacot, Rose-Marie Javier, Guillaume Jean, Claude Jeandel, Dominique Joly, Peter Kamenicky, Bertrand Knebelmann, Marie-Hélène Lafage-Proust, Yves LeBouc, Erick Legrand, Florence Levy-Weil, Agnès Linglart, Laurent Machet, Emmanuel Maheu, Eric Mallet, Christian Marcelli, Pierre Marès, Christophe Mariat, Gérard Maruani, Yves Maugars, France Montagnon, Bruno Moulin, Philippe Orcel, Henri Partouche, Virginie Personne, Charles Pierrot-Deseilligny, Michel Polak, Claire Pouteil-Noble, Dominique Prié, Agathe Raynaud-Simon, Yves Rolland, Jean-Louis Sadoul, Bernard Salle, Corinne Sault, Anne-Marie Schott, Isabelle Sermet-Gaudelus, Martin Soubrier, Ivan Tack, Éric Thervet, Isabelle Tostivint, Philippe Touraine, Florence Tremollières, Pablo Urena-Torres, Jean-Paul Viard, Jean-Louis Wemeau, Georges Weryha, Norbert Winer, Jacques Young, Thierry Thomas, CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Régional d'Orléans (CHRO), Service de rhumatologie[Lille], Hôpital Roger Salengro [Lille]-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Hôpital Cochin [AP-HP], Service de médecine interne et gérontologie clinique [Angers], Université d'Angers (UA)-Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Hôpital Femme Mère Enfant [CHU - HCL] (HFME), Hospices Civils de Lyon (HCL), Centre Hospitalier Boulogne-sur-mer, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Service de gynécologie-obstétrique, médecine de la reproduction [Béclère], Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Antoine Béclère [Clamart], Centre de Recherche Saint-Antoine (UMRS893), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Euromov (EuroMov), Université de Montpellier (UM), Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service de rhumatologie, Centre Hospitalier Universitaire de Nice (CHU Nice)-Hôpital l'Archet, Hôpital de la Conception [CHU - APHM] (LA CONCEPTION), Neuroprotection du Cerveau en Développement / Promoting Research Oriented Towards Early Cns Therapies (PROTECT), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Robert Debré-Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris Diderot - Paris 7 (UPD7), Service Endocrinologie, maladies métaboliques et nutrition [CHU Toulouse], Pôle Cardiovasculaire et Métabolique [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Biologie du Cancer et de l'Infection (BCI ), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Récepteurs stéroïdiens : physiopathologie endocrinienne et métabolique, Université Paris-Sud - Paris 11 (UP11)-IFR93-Institut National de la Santé et de la Recherche Médicale (INSERM), Physiopathologie, diagnostic et traitements des maladies osseuses / Pathophysiology, Diagnosis & Treatments of Bone Diseases (LYOS), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM), Endocrinologie pédiatrique[CHU Angers], Physiopathologie des maladies génétiques d'expression pédiatrique, Os et articulations, Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Fibrose hépatique et cancer du foie, Université Bordeaux Segalen - Bordeaux 2-IFR66-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Néphrologie-transplantation-dialyse [Bordeaux], CHU Bordeaux [Bordeaux], Centre de recherche Croissance et signalisation (UMR_S 845), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Nutrition [Cergy] (N - cabinet libéral ), Service d'Endocrinologie - Diabète - Nutrition [Reims], Université de Reims Champagne-Ardenne (URCA)-Hôpital Robert Debré-Centre Hospitalier Universitaire de Reims (CHU Reims), Hôpital Robert Debré, Centre Hospitalier Le Mans (CH Le Mans), Mécanismes physiologiques et conséquences des calcifications cardiovasculaires: rôle des remodelages cardiovasculaires et osseux, Université de Picardie Jules Verne (UPJV)-Institut National de la Santé et de la Recherche Médicale (INSERM), Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Institut National de la Recherche Agronomique (INRA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM), Foie, métabolismes et cancer, Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Service de rhumatologie [Rennes] = Rheumatology [Rennes], CHU Pontchaillou [Rennes], Service de Physiologie [Georges-Pompidou], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Université Paris Descartes - Paris 5 (UPD5), CHU Strasbourg, Institut de recherche en cancérologie de Montpellier (IRCM - U896 Inserm - UM1), Université Montpellier 1 (UM1)-CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Centre de Rein Artificiel [Tassin la demi-lune] (CRA), Université Montpellier 1 (UM1), AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Tissu Osseux et Contraintes Mecaniques (LBTO), Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Trousseau, Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Centre Hospitalier Victor Dupouy, Immunologie et génétique du diabète de type 1, génétique multifactorielle en endocrinologie pédiatrique (U986), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Rouen, Normandie Université (NU), Service de Rhumatologie [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne), Service de Rhumatologie, Hôtel-Dieu, Cabinet de Rhumatologie [Saint-Etienne] (CdR), Hôpital Lariboisière-Fernand-Widal [APHP], Département de Médecine Générale, Université Paris Cité (UPCité), Service de Neurologie [CHU Pitié-Salpêtrière], IFR70-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut Cochin (IC UM3 (UMR 8104 / U1016)), Hôpital Edouard Herriot [CHU - HCL], CIC Hôpital Bichat, AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-UFR de Médecine, Gérontopôle, Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps (LEASP), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Service d'Endocrinologie (NICE - Endocrino), Centre Hospitalier Universitaire de Nice (CHU Nice), Académie nationale de médecine, Eurofins Biomnis, CHU Gabriel Montpied [Clermont-Ferrand], CHU Clermont-Ferrand, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pitié-Salpêtrière [AP-HP], Université Pierre et Marie Curie - Paris 6 (UPMC), Service Obstétrique [CHU Toulouse], Pôle Femme-Mère-Couple [CHU Toulouse], Clinique du Landy [Saint-Ouen] (CL), Hôpital Hôtel-Dieu [Paris], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service d'Endocrinologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Service de Gynécologie Obstétrique (NANTES - Gynéco Obstétrique), Centre hospitalier universitaire de Nantes (CHU Nantes), Institut Gustave Roussy (IGR), Service d'endocrinologie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Bicêtre, and Jonchère, Laurent
Subjects: medicine.medical_specialty, Malabsorption, [SDV]Life Sciences [q-bio], MathematicsofComputing_GENERAL, [SDV.CAN]Life Sciences [q-bio]/Cancer, Phosphorus metabolism disorder, GeneralLiterature_MISCELLANEOUS, Phosphorus metabolism, InformationSystems_GENERAL, [SDV.CAN] Life Sciences [q-bio]/Cancer, Malabsorption Syndromes, Calcium Metabolism Disorders, Internal medicine, medicine, Serum vitamin D measurement, Vitamin D and neurology, Humans, Renal Insufficiency, Chronic, Renal Insufficiency, Chronic, Vitamin D, ComputingMilieux_MISCELLANEOUS, MESH: Bone Diseases / blood, Calcium Metabolism Disorders / blood, Malabsorption Syndromes / blood, Phosphorus Metabolism Disorders / blood, Renal Insufficiency, Chronic / blood, Vitamin D / blood, business.industry, Phosphorus Metabolism Disorders, General Medicine, medicine.disease, 3. Good health, [SDV] Life Sciences [q-bio], Endocrinology, Malabsorption syndromes, Bone Diseases, business, Kidney disease
Abstract: La mesure de la concentration serique de 25-hydroxy vitamines D (25OHD) permet d’evaluer le statut vitaminique D d’un individu. Ceci ne signifie pas qu’il faille doser ce parametre biologique chez tous les patients. Le nombre de prescriptions de dosages de 25OHD a pourtant decuple en France entre 2005 et 2013 generant un cout important de remboursement pour la Caisse nationale de l’assurance-maladie des travailleurs salaries (CNAMTS) ce qui l’a conduit, logiquement, a la saisine [...]
Published: 2014
Full Text: View/download PDF

5. Rapport de la HAS sur les dosages de vitamine D : ne passons pas d’une situation extrême à une autre situation tout aussi extrême

Author: Jean-Claude Souberbielle, Claude Laurent Benhamou, Bernard Cortet, Mickael Rousière, Christian Roux, Vered Abitbol, Maurice Audran, Justine Bachetta, Olivier Beauchet, Hubert Blain, Véronique Breuil, Karine Briot, Philippe Brunet, Philippe Chanson, Catherine Cormier, Marie Courbebaisse, Patrice Fardellone, Denis Fouque, Gérard Friedlander, Jean-Bernard Gauvain, Lionel Groussin, Pascal Houillier, William Jacot, Guillaume Jean, Peter Kamenicky, Marie-Hélène Lafage-Proust, Erick Legrand, Florence Levy-Weil, Agnès Linglart, Eric Mallet, Christian Marcelli, Gérard Maruani, France Montagnon, Virginie Personne, Dominique Prié, Agathe Raynaud-Simon, Yves Rolland, Bernard Salle, Corinne Sault, Anne-Marie Schott, Eric Thervet, Pablo Urena-Torres, Jean-Paul Viard, Georges Weryha, Charles Pierrot-Deseilligny, Jacques Young, and Thierry Thomas
Subjects: business.industry, Medicine, General Medicine, business, Humanities
Published: 2014
Full Text: View/download PDF

6. La vitamine D en pédiatrie

Author: Eric Mallet and Michel Vidailhet
Subjects: Vitamin, Pediatrics, medicine.medical_specialty, business.industry, Dark skin, Rickets, General Medicine, medicine.disease, vitamin D deficiency, Nutritional Rickets, chemistry.chemical_compound, chemistry, Dietary Reference Intake, medicine, Vitamin D and neurology, Hypocalcaemia, business
Abstract: Infantile Nutritional Rickets has disappeared almost completely in France since 1992 as vitamin D enriched formula availability and previous vitamin D supplementation of infants. The search of evocative symptoms of rickets should be a routine procedure in infants, in particular in case of insufficient vitamin D intake i.e. breastfeeding, and the possibility of vitamin D resistant rickets. Hypocalcaemia occurs not only at the first but also the advanced stages of vitamin D deficiency, and may be responsible for severe cardiologic, neurologic or respiratory complications with possibility of infant death. For the young children between 1 and 5 years and for adolescents, vitamin D insufficiency is responsible for poor skeletal mineralization, loss of bone strength, and a reduction of peak of bone mineral mass at the end of puberty. The new Dietary Reference Intakes (DRI, 2011) increased greatly the Recommended Dietary allowances (RDA) from 200 to 600 IU/d (15 μg/d) for individuals from 1 to 70 years of age. These levels are not reached in winter, even in countries, like USA and Canada, where vitamin D milk fortification is mandatory and others like Japan and North-European countries despite high fish consumption. From 1 to 5 years of age and during adolescence, a winter vitamin D3 supplementation is necessary with 80.000 or 100.000 IU periodic loads every 3 months i.e. in November and February. In cases of an underlying risk, i.e. insufficient vitamin D photosynthesis in summertime (dark skin, wearing heavily skin-covering clothes, or several skin diseases), or digestive, renal or nutritional pathologies, use of some drugs, loading dose of 80.000 or 100.000 IU, every 3 months should be administered over the year.
Published: 2013
Full Text: View/download PDF

7. French law: what about a reasoned reimbursement of serum vitamin D assays?

Author: Jean-Claude Souberbielle, Claude Laurent Benhamou, Bernard Cortet, Mickael Rousière, Christian Roux, Vered Abitbol, Cédric Annweiler, Maurice Audran, Justine Bacchetta, Pierre Bataille, Olivier Beauchet, Rémi Bardet, Alexandra Benachi, Francis Berenbaum, Hubert Blain, Françoise Borson-Chazot, Véronique Breuil, Karine Briot, Philippe Brunet, Jean-Claude Carel, Philippe Caron, Olivier Chabre, Philippe Chanson, Roland Chapurlat, Pierre Cochat, Régis Coutant, Sophie Christin-Maitre, Martine Cohen-Solal, Christian Combe, Catherine Cormier, Marie Courbebaisse, Grégory Debrus, Brigitte Delemer, Georges Deschenes, Marc Duquenne, Guillaume Duval, Patrice Fardellone, Denis Fouque, Gérard Friedlander, Jean-Bernard Gauvain, Lionel Groussin, Pascal Guggenbuhl, Pascal Houillier, Thierry Hannedouche, William Jacot, Rose-Marie Javier, Guillaume Jean, Claude Jeandel, Dominique Joly, Peter Kamenicky, Bertrand Knebelmann, Marie-Hélène Lafage-Proust, Yves LeBouc, Erick Legrand, Florence Levy-Weil, Agnès Linglart, Laurent Machet, Emmanuel Maheu, Eric Mallet, Christian Marcelli, Pierre Marès, Christophe Mariat, Gérard Maruani, Yves Maugars, France Montagnon, Bruno Moulin, Philippe Orcel, Henri Partouche, Virginie Personne, Charles Pierrot-Deseilligny, Michel Polak, Claire Pouteil-Noble, Dominique Prié, Agathe Raynaud-Simon, Yves Rolland, Jean-Louis Sadoul, Bernard Salle, Corinne Sault, Anne-Marie Schott, Isabelle Sermet-Gaudelus, Martin Soubrier, Ivan Tack, Eric Thervet, Isabelle Tostivint, Philippe Touraine, Florence Tremollières, Pablo Urena-Torres, Jean-Paul Viard, Jean-Louis Wemeau, Georges Weryha, Norbert Winer, Jacques Young, Thierry Thomas, CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Laboratoire d'Informatique de Nantes Atlantique (LINA), Mines Nantes (Mines Nantes)-Université de Nantes (UN)-Centre National de la Recherche Scientifique (CNRS), Service de rhumatologie[Lille], Hôpital Roger Salengro [Lille]-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Laboratoire d'aérologie (LAERO), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Observatoire Midi-Pyrénées (OMP), Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National d'Études Spatiales [Toulouse] (CNES)-Centre National de la Recherche Scientifique (CNRS)-Météo-France -Institut de Recherche pour le Développement (IRD)-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National d'Études Spatiales [Toulouse] (CNES)-Centre National de la Recherche Scientifique (CNRS)-Météo-France -Centre National de la Recherche Scientifique (CNRS), Laboratoire des Matériels Électriques (EDF R&D LME), EDF R&D (EDF R&D), EDF (EDF)-EDF (EDF), Centre d'Analyse et d'Intervention Sociologiques (CADIS), École des hautes études en sciences sociales (EHESS)-Centre National de la Recherche Scientifique (CNRS), Département de Médecine Interne et Gérontologie clinique, Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), Service de gynécologie-obstétrique, médecine de la reproduction [Béclère], Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Antoine Béclère [Clamart], Centre de Recherche Saint-Antoine (UMRS893), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Department of Geriatrics - Efficiency and Deficiency Laboratory, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service de rhumatologie, Centre Hospitalier Universitaire de Nice (CHU Nice)-Hôpital l'Archet, Vascular research center of Marseille (VRCM), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Trigone-CIREL, Centre Interuniversitaire de Recherche en Education de Lille - ULR 4354 (CIREL), Université de Lille-Université de Lille, Signalisation Hormonale, Physiopathologie Endocrinienne et Métabolique, Université Paris-Sud - Paris 11 (UP11)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Service de rhumatologie [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Biologie de l'Os et du Cartilage : Régulations et Ciblages Thérapeutiques (BIOSCAR (UMR_S_1132 / U1132)), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Rhumatologie [CHU Lariboisière], Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Unité Expérimentale Recherches Intégrées - Gotheron (UERI), Institut National de la Recherche Agronomique (INRA), Institut Cochin (IC UM3 (UMR 8104 / U1016)), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Unité de Néphrologie Pédiatrique, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Robert Debré, Université de Bordeaux (UB), Mécanismes physiopathologiques et conséquences des calcifications vasculaires - UR UPJV 7517 (MP3CV), Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, Motricité - Plasticité, Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Necker Enfants-Malades (INEM - UM 111 (UMR 8253 / U1151)), Centre de recherche sur le développement territorial (CRDT), Centre de recherche sur le développement territorial, CHU Pontchaillou [Rennes], Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Institut Pascal (IP), Université Blaise Pascal - Clermont-Ferrand 2 (UBP)-SIGMA Clermont (SIGMA Clermont)-Centre National de la Recherche Scientifique (CNRS), Service de rhumatologie [Nantes], Université de Nantes (UN)-Hôtel-Dieu-Centre hospitalier universitaire de Nantes (CHU Nantes), Information – Technologies – Analyse Environnementale – Procédés Agricoles (UMR ITAP), Institut national de recherche en sciences et technologies pour l'environnement et l'agriculture (IRSTEA)-Institut national d’études supérieures agronomiques de Montpellier (Montpellier SupAgro), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Lariboisière-Fernand-Widal [APHP], Centre de Physique Théorique [Palaiseau] (CPHT), École polytechnique (X)-Centre National de la Recherche Scientifique (CNRS), Département de Médecine Générale, Université Paris Descartes - Paris 5 (UPD5), CHU Pitié-Salpêtrière [AP-HP], Service de néphrologie et transplantation, Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Centre de recherche Croissance et signalisation (UMR_S 845), Service d'Endocrinologie (NICE - Endocrino), Centre Hospitalier Universitaire de Nice (CHU Nice), CIC Cochin Pasteur (CIC 1417), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôtel-Dieu-Université Paris Descartes - Paris 5 (UPD5)-Groupe hospitalier Broca-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Gabriel Montpied [Clermont-Ferrand], CHU Clermont-Ferrand, CPMF2 - Flemish Cluster Predictive Microbiology in Foods - www.cpmf2.be BioTeC - Chemical and Biochemical Process Technology and Control Department of Chemical Engineering, Catholic University of Leuven - Katholieke Universiteit Leuven (KU Leuven), Université Pierre et Marie Curie - Paris 6 (UPMC), Centre de ménopause, Centre de Diagnostic et de Thérapeutique, Hôpital de l’Hôtel-Dieu [Paris], Université Paris Descartes - Faculté de Médecine (UPD5 Médecine), Service d'Endocrinologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Service d'obstétrique-gynécologie [Nantes], Centre hospitalier universitaire de Nantes (CHU Nantes), Institut für Kernphysik der Universität zu Köln, Universität zu Köln = University of Cologne, Centre National de la Recherche Scientifique (CNRS)-Mines Nantes (Mines Nantes)-Université de Nantes (UN), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Observatoire Midi-Pyrénées (OMP), Météo France-Centre National d'Études Spatiales [Toulouse] (CNES)-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Météo France-Centre National d'Études Spatiales [Toulouse] (CNES)-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Centre National de la Recherche Scientifique (CNRS), Service de rhumatologie [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Eq 4, Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Groupement Hospitalier Lyon-Est (GHE), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL)-Centre de médecine nucléaire, Fédération d'endocrinologie-Groupement hospitalier Lyon-Est-Fédération d'endocrinologie-Groupement hospitalier Lyon-Est, Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro), Centre National de la Recherche Scientifique (CNRS)-École polytechnique (X), Service de neurologie 1 [CHU Pitié-Salpétrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre des Pathologies gynécologiques Rares [CHU Pitié-Salpêtrière], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut E3M [CHU Pitié-Salpêtrière], Hôpital Paule de Viguier, CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse], Universität zu Köln, Hôpital Roger Salengro-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Laboratoire d'aérologie (LA), Centre National de la Recherche Scientifique (CNRS)-Observatoire Midi-Pyrénées (OMP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées, Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Antoine Béclère, Centre de Recherche Saint-Antoine (CR Saint-Antoine), Service de rhumatologie, inflammation-immunopathologie- biothérapie [CHU Saint-Antoine] (DHU i2B ), CHU Saint-Antoine [APHP]-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Centre de Recherche en Cancérologie de Lyon (CRCL), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Groupement Hospitalier Lyon-Est (GHE), Centre Interuniversitaire de Recherche en Education de Lille (CIREL) - EA 4354 (CIREL), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Cochin [AP-HP], Hôpital Lariboisière, Unité de Recherches Intégrées - Gotheron (GOTH RI UERI), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Robert Debré, Laboratoire de génie chimique [ancien site de Basso-Cambo] (LGC), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Blaise Pascal - Clermont-Ferrand 2 (UBP)-Sigma CLERMONT (Sigma CLERMONT)-Centre National de la Recherche Scientifique (CNRS), Institut national d’études supérieures agronomiques de Montpellier (Montpellier SupAgro)-Institut national de recherche en sciences et technologies pour l'environnement et l'agriculture (IRSTEA), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Lariboisière, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Pitié-Salpêtrière [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Cochin [AP-HP]-Hôtel-Dieu-Université Paris Descartes - Paris 5 (UPD5)-Groupe hospitalier Broca-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Gabriel Montpied (CHU), CHU Pitié-Salpêtrière [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Institut für Kernphysik - Universität zu Köln, Institut de Recherche pour le Développement (IRD)-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National d'Études Spatiales [Toulouse] (CNES)-Centre National de la Recherche Scientifique (CNRS)-Université Fédérale Toulouse Midi-Pyrénées-Météo-France -Institut de Recherche pour le Développement (IRD)-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National d'Études Spatiales [Toulouse] (CNES)-Centre National de la Recherche Scientifique (CNRS)-Météo-France -Centre National de la Recherche Scientifique (CNRS), Service de Neurologie [CHU Pitié-Salpêtrière], IFR70-CHU Pitié-Salpêtrière [AP-HP], AP-HP - Hôpital Antoine Béclère [Clamart], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11), Institut National de la Santé et de la Recherche Médicale (INSERM)-Aix Marseille Université (AMU), AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Sud - Paris 11 (UP11), Laboratoire d'Informatique de Nantes Atlantique ( LINA ), Centre National de la Recherche Scientifique ( CNRS ) -Mines Nantes ( Mines Nantes ) -Université de Nantes ( UN ), Hôpital Roger Salengro-Centre Hospitalier Régional Universitaire [Lille] ( CHRU Lille ), Laboratoire d'aérologie - LA ( LA ), Université Toulouse III - Paul Sabatier ( UPS ), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut national des sciences de l'Univers ( INSU - CNRS ) -Observatoire Midi-Pyrénées ( OMP ) -Centre National de la Recherche Scientifique ( CNRS ), Laboratoire des Matériels Électriques ( EDF R&D LME ), EDF R&D ( EDF R&D ), EDF ( EDF ) -EDF ( EDF ), Centre d'Analyse et d'Intervention Sociologiques ( CADIS ), École des hautes études en sciences sociales ( EHESS ) -Centre National de la Recherche Scientifique ( CNRS ), CHU Angers, Université Paris-Sud - Paris 11 ( UP11 ) -Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Antoine Béclère, Centre de Recherche Saint-Antoine ( CR Saint-Antoine ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Pierre et Marie Curie - Paris 6 ( UPMC ), Service de rhumatologie, inflammation-immunopathologie- biothérapie [CHU Saint-Antoine] ( DHU i2B ), Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Saint-Antoine [APHP], Centre Hospitalier Régional Universitaire [Montpellier] ( CHRU Montpellier ), Centre de Recherche en Cancérologie de Lyon ( CRCL ), Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ) -Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ) -Groupement Hospitalier Lyon-Est ( GHE ), Hospices Civils de Lyon ( HCL ) -Hospices Civils de Lyon ( HCL ) -Centre de médecine nucléaire, CHU Nice-Hôpital l'Archet, Vascular research center of Marseille ( VRCM ), Aix Marseille Université ( AMU ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Centre Interuniversitaire de Recherche en Education de Lille (CIREL) - EA 4354 ( CIREL ), Université Paris-Sud - Paris 11 ( UP11 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Cochin [AP-HP], Biologie de l'Os et du Cartilage : Régulations et Ciblages Thérapeutiques ( BIOSCAR ), Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Lariboisière-Université Paris Diderot - Paris 7 ( UPD7 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Unité de Recherches Intégrées - Gotheron ( GOTH RI UERI ), Institut National de la Recherche Agronomique ( INRA ), Institut Cochin ( UM3 (UMR 8104 / U1016) ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Robert Debré, Laboratoire de génie chimique ( LGC ), Institut National Polytechnique [Toulouse] ( INP ) -Université Toulouse III - Paul Sabatier ( UPS ), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique ( CNRS ), Université de Bordeaux ( UB ), Université de Bourgogne ( UB ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Institut Necker Enfants-Malades (INEM) ( INEM - UM 111 (UMR 8253 / U1151) ), Centre de recherche sur le développement territorial ( CRDT ), Institut Pascal ( IP ), Université Blaise Pascal - Clermont-Ferrand 2 ( UBP ) -Sigma CLERMONT ( Sigma CLERMONT ) -Centre National de la Recherche Scientifique ( CNRS ), Université de Nantes ( UN ) -Hôtel-Dieu-Centre hospitalier universitaire de Nantes ( CHU Nantes ), Information – Technologies – Analyse Environnementale – Procédés Agricoles ( UMR ITAP ), Institut national de recherche en sciences et technologies pour l'environnement et l'agriculture ( IRSTEA ) -Institut national d’études supérieures agronomiques de Montpellier ( Montpellier SupAgro ), Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Lariboisière, Centre de Physique Théorique [Palaiseau] ( CPHT ), École polytechnique ( X ) -Centre National de la Recherche Scientifique ( CNRS ), Université Paris Descartes - Paris 5 ( UPD5 ), Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Pitié-Salpêtrière [APHP], Université de Lyon-Université de Lyon-Hospices Civils de Lyon ( HCL ) -Centre Hospitalier Lyon Sud [CHU - HCL] ( CHLS ), Hospices Civils de Lyon ( HCL ), Centre de recherche Croissance et signalisation ( UMR_S 845 ), Service d'Endocrinologie ( NICE - Endocrino ), CHU Nice, CIC Cochin Pasteur ( CIC 1417 ), Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Cochin [AP-HP]-Hôtel-Dieu-Université Paris Descartes - Paris 5 ( UPD5 ) -Groupe hospitalier Broca-Institut National de la Santé et de la Recherche Médicale ( INSERM ), CHU Gabriel Montpied ( CHU ), Katholieke Universiteit Leuven ( KU Leuven ), Université Pierre et Marie Curie - Paris 6 ( UPMC ), Assistance publique - Hôpitaux de Paris (AP-HP), Université Paris Descartes - Faculté de Médecine ( UPD5 Médecine ), Centre Hospitalier Régional Universitaire de Nancy ( CHRU Nancy ), Centre hospitalier universitaire de Nantes ( CHU Nantes ), and CRLCC Val d'Aurelle - Paul Lamarque-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Subjects: Male, recommendation, Pediatrics, medicine.medical_specialty, Malabsorption, Legislation, Medical, [SDV]Life Sciences [q-bio], Osteoporosis, 030209 endocrinology & metabolism, Rickets, vitamin D, osteomalacia, vitamin D deficiency, 03 medical and health sciences, 0302 clinical medicine, rickets, medicine, Vitamin D and neurology, Humans, 030212 general & internal medicine, Biological Psychiatry, Reimbursement, Aged, Aged, 80 and over, Osteomalacia, Hematologic Tests, [ SDV ] Life Sciences [q-bio], business.industry, Hydroxycholecalciferols, assay, medicine.disease, Obesity, reimbursement, osteoporosis, 3. Good health, Surgery, clinical practice, Neuropsychology and Physiological Psychology, Insurance, Health, Reimbursement, Female, Neurology (clinical), France, Geriatrics and Gerontology, business, calcium phosphorus evaluation, chronic kidney disease
Abstract: International audience; The number of serum 25-hydroxyvitamin D (25OHD) assays has increased tenfold in France in less than 10 years, sometimes for invalidated reasons. In 2013, the French National Authority for Health (Haute autorité de santé, or HAS) limited the indications for serum 25OHD measurements to rickets/osteomalacia, older adults with recurrent falls, monitoring of kidney transplant in adults, and surgical treatment of obesity in adults. Our aim here was to note that other indications for serum 25OHD measurements are supported by previous literature and by a number of national and international recommendations, in particular the following: any situation of bone fragility, any chronic renal failure
Published: 2016
Full Text: View/download PDF

8. Immunogenicity and safety of CRM197 conjugated 9-valent pneumococcal and meningococcal C combination vaccine in healthy infants

Author: Eric Mallet, Elisabeth Brachet, Philip Fernsten, France Laudat, Ahmad Razmpour, and William C. Gruber
Subjects: Serotype, General Veterinary, General Immunology and Microbiology, biology, business.industry, Neisseria meningitidis, Immunogenicity, Public Health, Environmental and Occupational Health, medicine.disease_cause, Virology, Immunoglobulin G, Pneumococcal conjugate vaccine, Infectious Diseases, Antigen, Conjugate vaccine, Streptococcus pneumoniae, medicine, biology.protein, Molecular Medicine, business, medicine.drug
Abstract: Streptococcus pneumoniae and Neisseria meningitidis cause invasive disease in children aged
Published: 2011
Full Text: View/download PDF

9. Infantile Hypercalcemia and Hypercalciuria: New Insights into a Vitamin D-Dependent Mechanism and Response to Ketoconazole Treatment

Author: Agnès Linglart, Frédéric Jehan, Eric Mallet, H. Guillozo, Minh Nguyen, Henri Boutignon, and Michèle Garabédian
Subjects: Male, Vitamin, medicine.medical_specialty, Calcitriol, Hypercalciuria, Parathyroid hormone, Calcitriol receptor, chemistry.chemical_compound, Blood serum, Internal medicine, medicine, Vitamin D and neurology, Humans, Vitamin D, Vitamin D3 24-Hydroxylase, Polymorphism, Genetic, business.industry, Infant, Newborn, Infant, medicine.disease, Fibroblast Growth Factor-23, Ketoconazole, Endocrinology, Haplotypes, chemistry, Parathyroid Hormone, Steroid Hydroxylases, Pediatrics, Perinatology and Child Health, Hypercalcemia, Receptors, Calcitriol, Calcium, Female, business, 24,25-Dihydroxycholecalciferol, medicine.drug
Abstract: Objective To analyze vitamin D metabolism and response to ketoconazole, an imidazole derivative that inhibits the vitamin D-1-hydroxylase, in infants with idiopathic hypercalcemia, and hypercalciuria. Study design Twenty infants (4 days-17 months) with hypercalcemia, severe hypercalciuria, and low parathyroid hormone level, (10 had nephrocalcinosis), including 10 treated with ketoconazole (3-9 mg/kg/day), were followed to the age of 2 to 51 months. Vitamin D receptor expression (VDR), 24-hydroxylase activity, and functional gene polymorphisms of vitamin D metabolism regulators VDR(rs4516035), 1-hydroxylase(rs10877012), 24-hydroxylase(rs2248359), FGF23(rs7955866), Klotho(rs9536314, rs564481, rs648202), were evaluated. Results Serum calcium levels, which occurred faster in the ketoconazole group (0.7 ± 0.2 versus 2.4 ± 0.6 months; P = .0076), and urinary calcium excretion (2.5 ± 0.5 versus 4.2 ± 1.7 months) normalized in all patients. Serum 1,25-(OH)2D levels were high normal and positively correlated to 25-(OH)D levels. Serum 24,25-(OH)2D levels were low normal, and skin fibroblasts from 1 patient showed defective up-regulation of the 24-hydroxylase by 1,25-(OH)2D despite normal VDR binding ability. An abnormally low prevalence of haplotype CC/CC for H589H/A749A in Klotho gene was found in patients and family members. Conclusions Ketoconazole is a potentially useful and safe agent for treatment of infantile hypercalcemia. Abnormal vitamin D metabolism is suggested as the mechanism, possibly involving defective up-regulation of the 24-hydroxylase by 1,25-(OH)2D3, and the klotho-FGF23 axis.
Published: 2010
Full Text: View/download PDF

10. Administration orale hivernale d’une dose unique de 200 000 UI de vitamine D3 chez l’adolescent en région normande : évaluation de sa tolérance et du statut vitaminique D obtenu

Author: Eric Mallet, J.-P. Basuyau, F. Philippe, and Mireille Castanet
Subjects: Vitamin, medicine.medical_specialty, Pediatrics, business.industry, Parathyroid hormone, chemistry.chemical_element, Calcium, Loading dose, Urinary calcium, chemistry.chemical_compound, Endocrinology, chemistry, Internal medicine, Pediatrics, Perinatology and Child Health, medicine, Vitamin D and neurology, Calcifediol, Cholecalciferol, business
Abstract: Adolescence, a period of growth and acquisition of bone mass, requires adequate calcium and vitamin D intake. This study was designed to assess the impact of a single loading dose of 200,000 IU of vitamin D(3) on the winter vitamin D status of healthy adolescents. Vitamin D status was assessed by 25-OH-D levels before, 3 weeks, and 3 months after this single dose, and safety was assessed by serum calcium and PTH and urinary calcium excretion in random samples from 27, 23, and 17 healthy adolescents derived from the same institution. The 25-OH-D peak value 2 weeks after the vitamin D supplement of 71-129 nmol/l (mean, 96 nmol/l), and a residual level at 3 months of 29-83 nmol/l (mean, 57 nmol/l) serum calcium and urinary calcium excretion expressed by the calcium/creatinine ratio were normal and stable at 2 weeks and 3 months, remaining less than 0.5 for the calcium/creatinine ratio. This simple measure, ensuring good compliance during adolescence, ensures optimal winter vitamin D status with no signs of overload.
Published: 2010
Full Text: View/download PDF

11. Primary Hyperparathyroidism in Neonates and Childhood

Author: Eric Mallet
Subjects: Hyperparathyroidism, medicine.medical_specialty, Pediatrics, medicine.diagnostic_test, business.industry, Endocrinology, Diabetes and Metabolism, Incidence (epidemiology), Retrospective cohort study, medicine.disease, Scintigraphy, Surgery, Endocrinology, Pediatrics, Perinatology and Child Health, Epidemiology, medicine, Endocrine system, Multiple endocrine neoplasia, business, Primary hyperparathyroidism
Abstract: Objectives: Primary hyperparathyroidism (HP1) in childhood is thought to be extremely rare. Its exact incidence remains unknown, as do the characteristics of HP1. A retrospective study collection was conducted on cases supplied by members of the Working Group on Calcium Metabolism throughout France over a 20-year period (1984–2004), since the availability of the intact parathormone (iPTH) radioimmunoassay. Results: 55 cases were collected of which 11 were neonates. Among the 44 children and adolescents, there were 18 male and 26 female patients, ranging in age from 6 to 18 (mean 13) years. 83% were symptomatic and 43% had nephrolithiasis. Symptoms were associated with high serum calcium and inappropriate iPTH levels. Ultrasonography and technetium-labelled methoxyisobutylisonitrile scintigraphy are useful tools for the preoperative localization of adenomas, particularly in adolescents. Intraoperative iPTH assays are effective in minimizing invasive parathyroidectomy. All patients, except neonates, underwent surgery: 29 adenomas and 11 hyperplasias were found. Two multiple endocrine neoplasias (MENs) were subsequently discovered. Since the calcium-sensing receptor (CaSR) mutation was reported, the form of management in neonates has become more medical (intravenous diphosphonates) than surgical. On follow-up no recurrence was observed except for MEN. Conclusion: These national results reflect HP1 epidemiology. HP1 is a rare entity and appears to be a severe disease in terms of symptoms with regard to management. The use of molecular biology tests could be useful not only in neonatal cases (CaSR mutation) but also prior to surgery in children (MEN mutation).
Published: 2008
Full Text: View/download PDF

12. Effect of partially methylated β cyclodextrin on percutaneous absorption of metopimazine

Author: Philippe Arnaud, Soizic Jezequel, Ludovic Didier, Abdussalam Sughir, Frédéric Bounoure, Mohamed Skiba, Eric Mallet, Malika Lahiani-Skiba, Cécile Barbot, Nutrition, inflammation et dysfonctionnement de l'axe intestin-cerveau (ADEN), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Appareil Digestif Environnement Nutrition (ADEN ), Normandie Université (NU)-Normandie Université (NU), CHU Rouen, and Normandie Université (NU)
Subjects: Octanol, Hydrochloride, Absorption (skin), 030226 pharmacology & pharmacy, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, medicine, Cyclodextrin, Solubility, Metopimazine, chemistry.chemical_classification, Chromatography, Percutaneous absorption, Franz’s cell, General Chemistry, [SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciences, Permeation, Condensed Matter Physics, 3. Good health, Partition coefficient, chemistry, 030220 oncology & carcinogenesis, Food Science, medicine.drug
Abstract: International audience; Metopimazine (MPZ) is an antiemetic drug used by oral and rectal administration. A transdermal delivery system of MPZ may present a great advantage for the treatment of nausea and vomiting to improve therapeutic adhesion. MPZ is a lipophilic drug with poor water solubility. Partially methyled β cyclodextrin (PMβ-CD) was tested to enhance percutaneous absorption of MPZ. Complex MPZ/cyclodextrin was characterized by Higushi’s phase solubility, Fourier transform infrared spectroscopy (FTIR) and differential scanning calorimetry (DSC) analyses and MPZ octanol partition coefficient was also determinated. The permeation of free MPZ and inclusion complex through pig skin were investigated using Franz’s cells. Four concentrations of cyclodextrins, 0, 5, 10 and 20% were tested. Partition coefficient was depending on pH of the solution. At pH 5.5, MPZ ionization increased the hydrophily (0.71) and at pH 10.3, non-ionized MPZ was the dominant form (591). The solubility of MPZ increased with the concentration of PMβ-CD and the phase solubility diagram is an Ap type. The used characterization analyses demonstrated the formation of an inclusion complex and this complex improved percutaneous absorption of MPZ. No MPZ flux was detected for a suspension of MPZ and it was more important with MPZ hydrochloride, 0.177 ± 0.044 μg/h/cm². Flux was increased to 0.570 ± 0.058 μg/h/cm² with a concentration of 20%. The use of cyclodextrin with MPZ hydrochloride increased also the percutaneous absorption with 0.549 ± 0.175 μg/h/cm² for a concentration of 5%, 0.435 ± 0.031 μg/h/cm² for a concentration of 10% and 0.474 ± 0.054 μg/h/cm² for a concentration of 20%. This study shows that PMβ-CD improves percutaneous penetration of MPZ. But the absorption is not enough to allow a therapeutic effect. Cyclodextrin complex increases MPZ solubility and this bioavailability at the skin surface, and cyclodextrin may also modify the barrier propriety of skin.
Published: 2007
Full Text: View/download PDF

13. Pharmacokinetic study of metopimazine by oral route in children

Author: Frédéric Bounoure, Mireille Castanet, Elodie Saussereau, Jean-Pierre Goullé, Eric Mallet, Mohamed Skiba, Service de pédiatrie médicale et médecine de l'adolescent [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Différenciation et communication neuronale et neuroendocrine (DC2N), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Groupe Hospitalier du Havre, Aliments Bioprocédés Toxicologie Environnements (ABTE), Université de Caen Normandie (UNICAEN), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU), Normandie Université (NU)-Normandie Université (NU)-Université de Caen Normandie (UNICAEN), and Leboeuf, Claire
Subjects: Antiemetic drug, Nausea, medicine.drug_class, Metabolite, Cmax, Pharmacology, 03 medical and health sciences, chemistry.chemical_compound, [SDV.MHEP.PED] Life Sciences [q-bio]/Human health and pathology/Pediatrics, 0302 clinical medicine, Pharmacokinetics, medicine, Antiemetic, General Pharmacology, Toxicology and Pharmaceutics, Adverse effect, Metopimazine, Children, 030304 developmental biology, 0303 health sciences, [SDV.MHEP.PED]Life Sciences [q-bio]/Human health and pathology/Pediatrics, business.industry, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, Original Articles, [SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, 3. Good health, Neurology, chemistry, [SDV.SP.PHARMA] Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, 030220 oncology & carcinogenesis, Vomiting, [SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, medicine.symptom, business, medicine.drug
Abstract: International audience; Metopimazine (MPZ) is an antiemetic considered as a currently used drug. In France, it has become the leading antiemetic mediator due to its good tolerance, however, its pharmacokinetics has never previously been studied in children. MPZ was administered by oral route to 8 children with a single dose of 0.33 mg/kg during an endocrine exploration using stimuli well known for its adverse emetic effects. We used biological remnants from sera following an hGH test in order to obtain the MPZ pharmacokinetics. Plasmatic concentrations of MPZ and the active acid metabolite AMPZ, were quantified by HPLC-MS/MS during a 270 min test period. MPZ is quickly absorbed with a median C max of 17.2 ng/mL at one hour and its half-life is 2.18 h. The plasmatic concentrations of AMPZ were higher than MPZ with a median C max of 76.3 ng/mL, a T max to 150 min and its concentration was approximately maintained at 50 ng/mL from 1 to 4 h. The plasmatic concentrations in children are similar to those observed in adults. No adverse effects, nausea or vomiting occurred during the trial. Therefore, these results confirm the MPZ dosage that should be used in children under 15 kg administered as 0.33 mg/kg up to 3 times a day.
Published: 2015
Full Text: View/download PDF

14. An easy-to-use technique to characterize cardiodynamics from first-return maps on ΔRR-intervals

Author: Adrien Kerfourn, Emeline Fresnel, Jean-François Muir, Valérie Messager, Christophe Letellier, Eric Mallet, Ubiratan S. Freitas, Emad Yacoub, Complexe de recherche interprofessionnel en aérothermochimie (CORIA), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut national des sciences appliquées Rouen Normandie (INSA Rouen Normandie), Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Institut National des Sciences Appliquées (INSA)-Centre National de la Recherche Scientifique (CNRS), Groupe de Recherche sur le Handicap Ventilatoire (GRHV), Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université (NU)-Normandie Université (NU)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-CHU Rouen, Normandie Université (NU), ADIR Association (ADIR), Service de Pédiatrie Médicale [Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, and Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN)
Subjects: Entropy, [SDV]Life Sciences [q-bio], 0206 medical engineering, Symbolic dynamics, General Physics and Astronomy, 02 engineering and technology, 030204 cardiovascular system & hematology, 03 medical and health sciences, Electrocardiography, 0302 clinical medicine, Rhythm, data base, Heart Rate, Heart rate, medicine, Heart rate variability, Entropy (information theory), Humans, human, procedures, reproducibility, Mathematical Physics, Mathematics, medicine.diagnostic_test, business.industry, Applied Mathematics, adult, Reproducibility of Results, Statistical and Nonlinear Physics, Pattern recognition, Atrial fibrillation, Heart, medicine.disease, 020601 biomedical engineering, Databases as Topic, Heart failure, physiology, [SDV.IB]Life Sciences [q-bio]/Bioengineering, Artificial intelligence, business
Abstract: International audience; Heart rate variability analysis using 24-h Holter monitoring is frequently performed to assess the cardiovascular status of a patient. The present retrospective study is based on the beat-to-beat interval variations or ΔRR, which offer a better view of the underlying structures governing the cardiodynamics than the common RR-intervals. By investigating data for three groups of adults (with normal sinus rhythm, congestive heart failure, and atrial fibrillation, respectively), we showed that the first-return maps built on ΔRR can be classified according to three structures: (i) a moderate central disk, (ii) a reduced central disk with well-defined segments, and (iii) a large triangular shape. These three very different structures can be distinguished by computing a Shannon entropy based on a symbolic dynamics and an asymmetry coefficient, here introduced to quantify the balance between accelerations and decelerations in the cardiac rhythm. The probability P111111 of successive heart beats without large beat-to-beat fluctuations allows to assess the regularity of the cardiodynamics. A characteristic time scale, corresponding to the partition inducing the largest Shannon entropy, was also introduced to quantify the ability of the heart to modulate its rhythm: it was significantly different for the three structures of first-return maps. A blind validation was performed to validate the technique.
Published: 2015
Full Text: View/download PDF

15. Lightwood Syndrome Revisited with a Novel Mutation in CYP24 and Vitamin D Supplement Recommendations

Author: Eric Mallet, Marie-Laure Kottler, and Mireille Castanet
Subjects: Male, medicine.medical_specialty, Parathyroid hormone, Polymerase Chain Reaction, Infant, Newborn, Diseases, LIGHTWOOD SYNDROME, CYP24A1, Internal medicine, Diseases in Twins, medicine, Vitamin D and neurology, Humans, Vitamin D, Infantile hypercalcemia, Vitamin D3 24-Hydroxylase, Alleles, business.industry, Siblings, Homozygote, Infant, Exons, Sequence Analysis, DNA, Pedigree, Endocrinology, Parathyroid Hormone, Dietary Supplements, Mutation, Steroid Hydroxylases, Pediatrics, Perinatology and Child Health, Vitamin D supplement, Hypercalcemia, Female, business, Novel mutation, Metabolism, Inborn Errors
Abstract: A novel mutation in CYP24A1 provides insight into idiopathic infantile hypercalcemia. In this report of 3 brothers, in twins supplemented with vitamin D (1900 IU/d), only the twin homozygous for CYP24A1 exhibited idiopathic infantile hypercalcemia. A subsequently affected younger brother given vitamin D 400 IU/d was not hypercalcemic.
Published: 2013
Full Text: View/download PDF

16. A liquid hexavalent combined vaccine against diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type B and hepatitis B: review of immunogenicity and safety

Author: Myron M. Levine, Jean-Pierre Carrière, Bernd H. Belohradsky, Carl-Erik Flodmark, Jacques Langue, Leif Gothefors, Johannes G. Liese, François Roussel, S. Stojanov, Güler Kanra, Alma Muñoz, François Undreiner, Agnes Hoffenbach, Florian Schödel, Luc Hessel, Patrice Camier, Eric Mallet, Philippe Reinert, and Rosanna Lagos
Subjects: Male, Hepatitis B vaccine, Vaccination schedule, Immunization, Secondary, medicine, Humans, Hepatitis B Vaccines, Vaccines, Combined, Seroconversion, Diphtheria-Tetanus-Pertussis Vaccine, Whooping cough, Haemophilus Vaccines, Reactogenicity, General Veterinary, General Immunology and Microbiology, Tetanus, business.industry, Diphtheria, Haemophilus influenzae type b, Public Health, Environmental and Occupational Health, Infant, medicine.disease, Poliovirus Vaccines, Vaccination, Infectious Diseases, Immunology, Molecular Medicine, Female, business
Abstract: To reduce the number of injections needed to comply with paediatric vaccination requirements, a liquid, hexavalent vaccine (DTaP-IPV-PRP-T-HBs; Hexavac; Aventis Pasteur MSD) has been developed for primary and booster vaccination of infants and toddlers. In extensive clinical studies, Hexavac has been shown to be highly immunogenic. Seroconversion or seroprotective titres of antibodies against all antigens were achieved in the majority of infants following a primary series of three doses administered at 1-2-month intervals from 2 months of age. Hexavac also induced immunologic memory, as evidenced by the anamnestic response to booster vaccination at 12-18 months of age. These responses were comparable with those seen following concomitant administration of Pentavac (DTaP-IPV//PRP-T) and monovalent hepatitis B vaccine (H-B-Vax II), and were also within the ranges observed for other relevant licensed vaccines. Clinical studies comparing the immunogenicity of Hexavac administered at either 2, 3 and 4 months or 2, 4 and 6 months demonstrated that it can be used by either vaccination schedule. A further study also supported the use of primary doses of Hexavac at 3 and 5 months with a booster at 12 months of age. Hexavac demonstrated a good reactogenicity and tolerability profile. The most frequently reported adverse events after both primary and booster doses were local reactions of redness and swelling/induration and a systemic response of mild fever, irrespective of the vaccine used for priming. Hexavac provided immunity against six important childhood diseases with a single injection at each visit.
Published: 2004
Full Text: View/download PDF

17. Antibody persistence against diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b (Hib) in 5–6-year-old children after primary vaccination and first booster with a pentavalent combined acellular pertussis vaccine: immunogenicity and tolerance of a tetravalent combined acellular pertussis vaccine given as a second booster

Author: Eric Mallet, Nicolas Mathieu, Jacques Langue, Noëlle Matisse, Benoît Soubeyrand, and Florence Boisnard
Subjects: Male, Bordetella pertussis, Immunization, Secondary, Booster dose, complex mixtures, Antibodies, medicine, Humans, Vaccines, Combined, Child, Diphtheria-Tetanus-Pertussis Vaccine, Whooping cough, Haemophilus Vaccines, Booster (rocketry), General Veterinary, General Immunology and Microbiology, biology, Tetanus, business.industry, Diphtheria, Vaccination, Haemophilus influenzae type b, Public Health, Environmental and Occupational Health, medicine.disease, biology.organism_classification, Virology, Poliovirus Vaccines, Infectious Diseases, Child, Preschool, Antibody Formation, Immunology, Molecular Medicine, Pertussis vaccine, Female, France, business, Immunologic Memory, medicine.drug
Abstract: The main objective of this study was to assess in 5–6-year-old French children ( n =234) the persistence of antibodies induced by a primary series vaccination (at 2–4 months of age) and a first booster (at 12–16 months of age) with a pentavalent two-component acellular pertussis combined vaccine (DTacP-IPV-Hib; Pentavac ® ). The second objective was to evaluate in these 5–6-year-old French children the safety and the immunogenicity of a tetravalent acellular pertussis combined vaccine (DTacP-IPV; Tetravac ® ) given as second booster. Results: Seroprotective antibody levels against diphtheria, tetanus, types 1–3 poliomyelitis and PRP were maintained 4–5 years after primary-vaccination and first booster with Pentavac ® . As expected, anti-PT antibodies levels were low, suggesting that children were not colonised by Bordetella pertussis . The second booster with Tetravac ® was well tolerated and elicited a strong booster response for all antigens. Conclusion: acellular pertussis combined vaccine, used in primary-vaccination, could be considered as having the same priming effect and the same efficacy as whole cell pertussis vaccine.
Published: 2004
Full Text: View/download PDF

18. GNAS1Lesions in Pseudohypoparathyroidism Ia and Ic: Genotype Phenotype Relationship and Evidence of the Maternal Transmission of the Hormonal Resistance

Author: Agnès Linglart, Jean Claude Carel, Michèle Garabédian, Eric Mallet, Tran Lé, and Marie Laure Kottler
Subjects: Adult, Male, musculoskeletal diseases, medicine.medical_specialty, Adolescent, Genotype, Endocrinology, Diabetes and Metabolism, Clinical Biochemistry, Fibrous Dysplasia, Polyostotic, Biochemistry, Endocrinology, Internal medicine, GTP-Binding Protein alpha Subunits, Gs, medicine, GNAS complex locus, Humans, Missense mutation, natural sciences, Allele, Child, Gene, Alleles, Pseudohypoparathyroidism, G alpha subunit, Hypocalcemia, biology, Biochemistry (medical), Infant, Newborn, Infant, Middle Aged, medicine.disease, Pedigree, Phenotype, Child, Preschool, Mutation, biology.protein, Female, STX16
Abstract: We conducted clinical and biological studies including screening for mutations in the gene encoding the alpha subunit of G(s) (GNAS1) in 30 subjects (21 unrelated families) with Albright's hereditary osteodystrophy (AHO), pseudohypoparathyroidism (PHP); and decreased erythrocyte G(s) activity (PHP-Ia; n = 19); AHO and decreased erythrocyte G(s) activity (isolated AHO; n = 10); or AHO, hormonal resistance, and normal erythrocyte G(s) activity (PHP-Ic; n = 1). A heterozygous GNAS1 gene lesion was found in 14 of 17 PHP-Ia index cases (82%), including 11 new mutations and a mutational hot-spot involving codons 189-190 (21%). These lesions lead to a truncated protein in all but three cases with missense mutations R280K, V159M, and D156N. In the patient diagnosed with PHP-Ic, G(s)alpha protein was shortened by just four amino acids, a finding consistent with the conservation of G(s) activity in erythrocytes and the loss of receptor contact. No GNAS1 lesions were found in individuals with isolated AHO that were not relatives to PHP-Ia patients (n = 5). Intrafamilial segregation analyses of the mutated GNAS1 allele in nine PHP-Ia patients established that the mutation had either occurred de novo on the maternal allele (n = 4) or had been transmitted by a mother with a mild phenotype (n = 5). This finding is consistent with an imprinting of GNAS1 playing a role in the clinical phenotype of loss of function mutations and with a functional maternal GNAS1 allele having a predominant role in preventing the hormonal resistance of PHP-Ia.
Published: 2002
Full Text: View/download PDF

19. Usefulness of bone density measurement in fallers

Author: Brigitte Letombe, Jean-Claude Souberbielle, Olivier Beauchet, Yves Rolland, Patrice Fardellone, Martine Cohen-Solal, Eric Mallet, Hubert Blain, Véronique Breuil, Christian Marcelli, Jean-Marc Feron, Bernard Cortet, Claude-Laurent Benhamou, Pascal Guggenbuhl, Jean-Bernard Gauvain, Roland Chapurlat, Michel Brazier, Karine Briot, Michel Laroche, Cédric Annweiler, Athanase Benetos, Patricia Dargent, François Puisieux, Olivier Hanon, Gilles Berrut, Bruno Sutter, Valérie Bousson, Patrick Seret, Maurice Audran, Georges Weryha, Thierry Thomas, Sauveur Bendavid, Eric Lespessailles, Christian Roux, Philippe Orcel, Laure Chapuis, Florence Trémollières, Sami Kolta, Department of Geriatrics - Efficiency and Deficiency Laboratory, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Département de Médecine Interne et Gérontologie clinique, Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), Service de médecine interne et gérontologie clinique [Angers], Université d'Angers (UA)-Centre Hospitalier Universitaire d'Angers (CHU Angers), Service de médecine gériatrique, Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Service de médecine aïgue gériatrique [Nantes], PRES Université Nantes Angers Le Mans (UNAM)-Centre hospitalier universitaire de Nantes (CHU Nantes), Groupe d'Études Remodelage Osseux et bioMatériaux (GEROM), Université d'Angers (UA), Médecine générale, Inconnu, Bioingénierie et Bioimagerie Ostéo-articulaires, Biomécanique et Biomatériaux Ostéo-Articulaires (B2OA (UMR_7052)), École nationale vétérinaire d'Alfort (ENVA)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS), Caractérisation du Tissu Osseux par Imagerie : techniques et applications, Service de rhumatologie [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de rhumatologie, CHU Amiens-Picardie, Centre Hospitalier Universitaire de Nice (CHU Nice)-Hôpital l'Archet, Centre hospitalier de Vitré, Physiopathologie, diagnostic et traitements des maladies osseuses / Pathophysiology, Diagnosis & Treatments of Bone Diseases (LYOS), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM), Os et articulations, Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de rhumatologie[Lille], Hôpital Roger Salengro [Lille]-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre de recherche en épidémiologie et santé des populations (CESP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Mécanismes physiologiques et conséquences des calcifications cardiovasculaires: rôle des remodelages cardiovasculaires et osseux, Université de Picardie Jules Verne (UPJV)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre de médecine gériatrique, Centre Hospitalier Régional d'Orléans (CHRO), Foie, métabolismes et cancer, Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Service de rhumatologie [Rennes] = Rheumatology [Rennes], CHU Pontchaillou [Rennes], AP-HP - Hôpital Cochin Broca Hôtel Dieu [Paris], Handicap, Activité, Vieillissement, Autonomie, Environnement (HAVAE), Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST), Université de Limoges (UNILIM)-Université de Limoges (UNILIM), Imagerie Multimodale Multiéchelle et Modélisation du Tissu Osseux et articulaire (I3MTO), Université d'Orléans (UO), Hôpital Jeanne de Flandres, Université de Lille, Droit et Santé-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre de référence des maladies rares du calcium et du phosphore, CHU Rouen, Normandie Université (NU)-Normandie Université (NU), Service de Rhumatologie [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Lariboisière-Fernand-Widal [APHP], Service de gériatrie, Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), laboratoire de physiologie, Université Paris Descartes - Paris 5 (UPD5), Institut Calot, Centre de ménopause, Hôpital Paule de Viguier, CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse], Service d'Endocrinologie [CHRU Nancy], Centre Hospitalier Régional Universitaire [Montpellier] ( CHRU Montpellier ), CHU Angers, Université d'Angers ( UA ) -CHU Angers, Centre Hospitalier Régional Universitaire de Nancy ( CHRU Nancy ), PRES Université Nantes Angers Le Mans ( UNAM ) -Centre hospitalier universitaire de Nantes ( CHU Nantes ), Remodelage osseux et biomatériaux, Université d'Angers ( UA ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Biomécanique et Biomatériaux Ostéo-Articulaires ( B2OA ), Université Paris Diderot - Paris 7 ( UPD7 ) -Ecole Nationale Vétérinaire d'Alfort-Centre National de la Recherche Scientifique ( CNRS ), Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Cochin [AP-HP]-Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Cochin [AP-HP], CHU Nice-Hôpital l'Archet, Physiopathologie, diagnostic et traitements des maladies osseuses / Pathophysiology, Diagnosis & Treatments of Bone Diseases ( LYOS ), Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Université Paris Diderot - Paris 7 ( UPD7 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Hôpital Roger Salengro-Centre Hospitalier Régional Universitaire [Lille] ( CHRU Lille ), Centre de recherche en épidémiologie et santé des populations ( CESP ), Université de Versailles Saint-Quentin-en-Yvelines ( UVSQ ) -Université Paris-Sud - Paris 11 ( UP11 ) -Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Université de Picardie Jules Verne ( UPJV ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Service de chirurgie orthopédique, CHU Saint-Antoine [APHP], Centre Hospitalier Régional d'Orléans ( CHR ), Université de Rennes 1 ( UR1 ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Hôpital Sud, Handicap, Activité, Vieillissement, Autonomie, Environnement ( HAVAE ), Institut Génomique, Environnement, Immunité, Santé, Thérapeutique ( GEIST ), Université de Limoges ( UNILIM ) -Université de Limoges ( UNILIM ), Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Cochin [AP-HP], Imagerie Multimodale Multiéchelle et Modélisation du Tissu Osseux et articulaire ( I3MTO ), Université d'Orléans ( UO ), Université de Lille, Droit et Santé-Centre Hospitalier Régional Universitaire [Lille] ( CHRU Lille ), CHU Caen, Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Lariboisière, Centre Hospitalier Régional Universitaire [Lille] ( CHRU Lille ), Université Paris Descartes - Paris 5 ( UPD5 ), Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS)-École nationale vétérinaire d'Alfort (ENVA), CHU Cochin [AP-HP]-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Cochin [AP-HP]-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Hôpital Roger Salengro-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Hôpital Paul Brousse-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris-Sud - Paris 11 (UP11)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Centre Hospitalier Régional d'Orléans (CHR), CHU Cochin [AP-HP]-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Lariboisière, École nationale vétérinaire - Alfort (ENVA)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), and Institut Calot [Fondation Hopale]
Subjects: musculoskeletal diseases, medicine.medical_specialty, Bone density, [SDV]Life Sciences [q-bio], Osteoporosis, Poison control, Absorptiometry, Photon, Rheumatology, Weight loss, Bone Density, Risk Factors, Injury prevention, Medicine, Humans, Dual-energy X-ray absorptiometry, Osteoporosis, Postmenopausal, Bone mineral, medicine.diagnostic_test, [ SDV ] Life Sciences [q-bio], business.industry, musculoskeletal, neural, and ocular physiology, medicine.disease, musculoskeletal system, 3. Good health, Sarcopenia, Physical therapy, Accidental Falls, Female, medicine.symptom, business
Abstract: International audience; The objective of this systematic literature review is to discuss the latest French recommendation issued in 2012 that a fall within the past year should lead to bone mineral density (BMD) measurement using dual-energy X-ray absorptiometry (DXA). This recommendation rests on four facts. First, osteoporosis and fall risk are the two leading risk factors for nonvertebral fractures in postmenopausal women. Second, BMD measurement using DXA supplies significant information on the fracture risk independently from the fall risk. Thus, when a fall occurs, the fracture risk increases as BMD decreases. Third, osteoporosis drugs have been proven effective in preventing fractures only in populations with osteoporosis defined based on BMD criteria. Finally, the prevalence of osteoporosis is high in patients who fall and increases in the presence of markers for frailty (e.g., recurrent falls, sarcopenia [low muscle mass and strength], limited mobility, and weight loss), which are risk factors for both osteoporosis and falls. Nevertheless, life expectancy should be taken into account when assessing the appropriateness of DXA in fallers, as osteoporosis treatments require at least 12months to decrease the fracture risk. Another relevant factor is the availability of DXA, which may be limited due to geographic factors, patient dependency, or severe cognitive impairments, for instance. Studies are needed to better determine how the fall risk and frailty should be incorporated into the fracture risk evaluation based on BMD and the FRAX® tool.
Published: 2014
Full Text: View/download PDF

20. Intérêt de l'ostéodensitométrie chez les sujets chuteurs

Author: Patrick Seret, Olivier Beauchet, Véronique Breuil, Laure Chapuis, Pascal Guggenbuhl, Michel Brazier, Yves Rolland, Christian Marcelli, Maurice Audran, Michel Laroche, Patrice Fardellone, Karine Briot, Florence Trémollières, Georges Weryha, Cédric Annweiler, Jean-Bernard Gauvain, Thierry Thomas, Sauveur Bendavid, Philippe Orcel, Athanase Benetos, Olivier Hanon, Claude-Laurent Benhamou, Eric Lespessailles, Jean-Marc Feron, Valérie Bousson, François Puisieux, Brigitte Letombe, Gilles Berrut, Christian Roux, Martine Cohen-Solal, Eric Mallet, Jean-Claude Souberbielle, Hubert Blain, Bruno Sutter, Bernard Cortet, Roland Chapurlat, Patricia Dargent, Sami Kolta, Department of Geriatrics - Efficiency and Deficiency Laboratory, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Gérontopôle, Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps (LEASP), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Toulouse [Toulouse], Département de Médecine Interne et Gérontologie clinique, Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), Service de médecine interne et gérontologie clinique [Angers], Université d'Angers (UA)-Centre Hospitalier Universitaire d'Angers (CHU Angers), Imagerie Multimodale Multiéchelle et Modélisation du Tissu Osseux et articulaire (I3MTO), Université d'Orléans (UO), Service de médecine gériatrique, Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Service de médecine aïgue gériatrique [Nantes], PRES Université Nantes Angers Le Mans (UNAM)-Centre hospitalier universitaire de Nantes (CHU Nantes), Groupe d'Études Remodelage Osseux et bioMatériaux (GEROM), Université d'Angers (UA), Médecine générale, Inconnu, Service de radiologie Ostéo-Articulaire, Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Caractérisation du Tissu Osseux par Imagerie : techniques et applications, Service de rhumatologie [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de rhumatologie, CHU Amiens-Picardie, Centre Hospitalier Universitaire de Nice (CHU Nice)-Hôpital l'Archet, Centre hospitalier de Vitré, Physiopathologie, diagnostic et traitements des maladies osseuses / Pathophysiology, Diagnosis & Treatments of Bone Diseases (LYOS), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM), Os et articulations, Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de rhumatologie[Lille], Hôpital Roger Salengro [Lille]-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Mécanismes physiologiques et conséquences des calcifications cardiovasculaires: rôle des remodelages cardiovasculaires et osseux, Université de Picardie Jules Verne (UPJV)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Saint-Antoine [AP-HP], Centre de médecine gériatrique, Centre Hospitalier Régional d'Orléans (CHRO), Foie, métabolismes et cancer, Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), AP-HP - Hôpital Cochin Broca Hôtel Dieu [Paris], Centre de rhumatologie, CHU Purpan, Hôpital Jeanne de Flandres, Université de Lille, Droit et Santé-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre de référence des maladies rares du calcium et du phosphore, CHU Rouen, Normandie Université (NU)-Normandie Université (NU), Service de Rhumatologie [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Lariboisière-Fernand-Widal [APHP], Service de gériatrie, Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre de recherche Croissance et signalisation (UMR_S 845), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut Calot, Institut Calot [Fondation Hopale], Centre de ménopause, Service d'Endocrinologie [CHRU Nancy], Biologie intégrative du tissu osseux, Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Centre de Rhumatologie [CHU Toulouse], Pôle Inflammation, infection, immunologie et loco-moteur [CHU Toulouse] (Pôle I3LM Toulouse), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Biologie Intégrative du Tissu Osseux (LBTO), Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Descartes - Paris 5 (UPD5), Hôpital Paule de Viguier, CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse], Centre Hospitalier Régional Universitaire [Montpellier] ( CHRU Montpellier ), Gérontopôle de Toulouse, CHU Toulouse [Toulouse], CHU Angers, Université d'Angers ( UA ) -CHU Angers, Imagerie Multimodale Multiéchelle et Modélisation du Tissu Osseux et articulaire ( I3MTO ), Université d'Orléans ( UO ), Centre Hospitalier Régional Universitaire de Nancy ( CHRU Nancy ), PRES Université Nantes Angers Le Mans ( UNAM ) -Centre hospitalier universitaire de Nantes ( CHU Nantes ), Remodelage osseux et biomatériaux, Université d'Angers ( UA ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Hôpital Lariboisière, Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Cochin [AP-HP]-Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Cochin [AP-HP], CHU Nice-Hôpital l'Archet, Physiopathologie, diagnostic et traitements des maladies osseuses / Pathophysiology, Diagnosis & Treatments of Bone Diseases ( LYOS ), Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Université Paris Diderot - Paris 7 ( UPD7 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Hôpital Roger Salengro-Centre Hospitalier Régional Universitaire [Lille] ( CHRU Lille ), Centre de recherche en épidémiologie et santé des populations ( CESP ), Université de Versailles Saint-Quentin-en-Yvelines ( UVSQ ) -Université Paris-Sud - Paris 11 ( UP11 ) -Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Université de Picardie Jules Verne ( UPJV ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Service de chirurgie orthopédique, CHU Saint-Antoine [APHP], Centre Hospitalier Régional d'Orléans ( CHR ), Université de Rennes 1 ( UR1 ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Cochin [AP-HP], Université de Lille, Droit et Santé-Centre Hospitalier Régional Universitaire [Lille] ( CHRU Lille ), CHU Caen, Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Lariboisière, Centre Hospitalier Régional Universitaire [Lille] ( CHRU Lille ), Centre de recherche Croissance et signalisation ( UMR_S 845 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), and Université Jean Monnet [Saint-Étienne] ( UJM ) -Institut National de la Santé et de la Recherche Médicale ( INSERM )
Subjects: [ SDV.MHEP.RSOA ] Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system, Rheumatology, Ostéodensitométrie, Prise en charge, [SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system, Ostéoporose, Recommandations, Chute, Fragilité
Abstract: National audience; La présente revue de la littérature a pour objectif d'argumenter les nouvelles recommandations françaises publiées en 2012 retenant le risque de chute, évalué par l'antécédent de chute dans la dernière année, comme indication de la mesure de la densité minérale osseuse (DMO) par l'absorptiométrie biphotonique par rayons X (DXA). Cette recommandation repose sur le fait que premièrement, l'ostéoporose et le risque de chute représentent les deux premiers facteurs de risque de fracture non vertébrale après la ménopause. Deuxièmement, la mesure de la DMO par DXA apporte une information significative sur le risque de fracture, indépendamment du risque de chute. Ainsi, un sujet chuteur aura d'autant plus de risque de se fracturer qu'il aura une DMO basse. Troisièmement, les traitements anti-ostéoporotiques n'ont montré une efficacité anti-fracturaire qu'en cas d'ostéoporose ostéodensitométrique. Quatrièmement, la prévalence de l'ostéoporose est élevée chez les sujets chuteurs d'autant que ceux-ci sont fragiles [chutes répétées, sarcopénie (faible masse et force musculaire), réduction de mobilité, perte de poids, en particulier], ces facteurs étant des facteurs de risque communs d'ostéoporose et de chute. Cependant, l'indication de la DXA doit être nuancée chez les sujets chuteurs dont l'espérance de vie est limitée, les traitements n'ayant montré une efficacité anti-fracturaire qu'après 12 mois d'administration et en cas de faible accessibilité à la DXA (éloignement, patients dépendants, ayant une altération cognitive sévère par exemple). Des travaux sont souhaitables pour mieux définir comment intégrer le risque de chute et la fragilité dans l'évaluation du risque de fracture par la DMO et le score FRAX®
Published: 2014
Full Text: View/download PDF

21. OSMOSIS: a new joint laboratory between SOFRADIR and ONERA for the development of advanced DDCA with integrated optics

Author: Yann Reibel, Eric Mallet, Serge Magli, Guillaume Druart, Pierre Jenouvrier, Mathieu Chambon, Noura Matallah, and Nicolas Guérineau
Subjects: Pixel, Payload, Infrared, Computer science, Detector, Multispectral image, Miniaturization, Systems engineering, Joint (building), Integrated optics, Focus (optics), Focal Plane Arrays, Remote sensing
Abstract: Today, both military and civilian applications require miniaturized optical systems in order to give an imagery function to vehicles with small payload capacity. After the development of megapixel focal plane arrays (FPA) with micro-sized pixels, this miniaturization will become feasible with the integration of optical functions in the detector area. In the field of cooled infrared imaging systems, the detector area is the Detector-Dewar-Cooler Assembly (DDCA). SOFRADIR and ONERA have launched a new research and innovation partnership, called OSMOSIS, to develop disruptive technologies for DDCA to improve the performance and compactness of optronic systems. With this collaboration, we will break down the technological barriers of DDCA, a sealed and cooled environment dedicated to the infrared detectors, to explore Dewar-level integration of optics. This technological breakthrough will bring more compact multipurpose thermal imaging products, as well as new thermal capabilities such as 3D imagery or multispectral imagery. Previous developments will be recalled (SOIE and FISBI cameras) and new developments will be presented. In particular, we will focus on a dual-band MWIR-LWIR camera and a multichannel camera.
Published: 2014
Full Text: View/download PDF

22. [HAS report on vitamin D measurement: don't go from an extreme situation to another as extreme situation]

Author: Jean-Claude, Souberbielle, Claude Laurent, Benhamou, Bernard, Cortet, Mickael, Rousière, Christian, Roux, Vered, Abitbol, Maurice, Audran, Justine, Bachetta, Olivier, Beauchet, Hubert, Blain, Véronique, Breuil, Karine, Briot, Philippe, Brunet, Philippe, Chanson, Catherine, Cormier, Marie, Courbebaisse, Patrice, Fardellone, Denis, Fouque, Gérard, Friedlander, Jean-Bernard, Gauvain, Lionel, Groussin, Pascal, Houillier, William, Jacot, Guillaume, Jean, Peter, Kamenicky, Marie-Hélène, Lafage-Proust, Erick, Legrand, Florence, Levy-Weil, Agnès, Linglart, Eric, Mallet, Christian, Marcelli, Gérard, Maruani, France, Montagnon, Virginie, Personne, Dominique, Prié, Agathe, Raynaud-Simon, Yves, Rolland, Bernard, Salle, Corinne, Sault, Anne-Marie, Schott, Eric, Thervet, Pablo, Urena-Torres, Jean-Paul, Viard, Georges, Weryha, Charles, Pierrot-Deseilligny, Jacques, Young, Thierry, Thomas, CRLC Val d'Aurelle-Paul Lamarque, CRLCC Val d'Aurelle - Paul Lamarque, Institut de recherche en cancérologie de Montpellier (IRCM - U896 Inserm - UM1), Université Montpellier 1 (UM1)-CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), CHU Saint-Etienne, AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Centre Hospitalier Victor Dupouy, CHU Rouen, Normandie Université (NU), Service de Rhumatologie [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), AP-HP - Hôpital Bichat - Claude Bernard [Paris], CHU Toulouse [Toulouse], Académie nationale de médecine, Biomnis Laboratory, Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Service de Néphrologie et Hémodialyse [CHU HEGP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Service de Neurologie [CHU Pitié-Salpêtrière], IFR70-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Régional d'Orléans (CHRO), Service de rhumatologie[Lille], Hôpital Roger Salengro [Lille]-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service de rhumatologie [CHU Saint-Antoine], CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Hôpital Cochin [AP-HP], Hôpital Femme Mère Enfant [CHU - HCL] (HFME), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Euromov (EuroMov), Université de Montpellier (UM), Centre Hospitalier Universitaire de Nice (CHU Nice), Assistance Publique - Hôpitaux de Marseille (APHM), CHU Amiens-Picardie, Service de neurologie 1 [CHU Pitié-Salpétrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], and Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)
Subjects: Vitamin D/administration & dosage/*blood, Dose-Response Relationship, Dose-Response Relationship, Drug, Humans, [SDV.CAN]Life Sciences [q-bio]/Cancer, Vitamin D, Drug, Vitamin D Deficiency, Vitamin D Deficiency/*diagnosis
Published: 2014
Full Text: View/download PDF

23. Infections cutanées sévères à Streptococcus pyogenes chez l’enfant : résultats d’une enquête multicentrique

Author: J.-M. Garnier, Eric Mallet, Philippe Reinert, Joël Gaudelus, E. Jeannot, A Bourrillon, C Dechamps, D. Gendrel, C. Olivier, B Lagardère, J.F. Duhamel, I Küpfer, J. Boulesteix, A. Labbe, A. Marie Cardine, K Billiemaz, and M. Meunier
Subjects: Gynecology, medicine.medical_specialty, business.industry, Pediatrics, Perinatology and Child Health, medicine, business
Abstract: Resume Objectif.– Le but a ete de recenser les cas pediatriques d’infections cutanees severes a Streptococcus pyogenes . En effet, depuis le debut des annees 1980, une augmentation de l’incidence de ces infections a S. pyogenes de serotype M1, M3 ou M5 etait rapportee chez l’adulte. Patients et methodes. – Une enquete retrospective a ete menee sur une periode de onze ans (1990-2000) aupres des membres du Groupe de pathologie infectieuse pediatrique exercant dans plusieurs centres hospitaliers regionaux ou generaux. Resultats. – Cette enquete a permis de recueillir trois cas de fasciites necrosantes et 15 cas de cellulites. Parmi les cellulites, cinq cas faisaient suite a une varicelle, les autres a un traumatisme benin ouvert. Le diagnostic bacteriologique a ete retenu a partir de prelevements locaux et d’hemocultures respectivement dans 14 et quatre cas. Le traitement initial comportait du cefotaxime dans onze cas, de la penicilline M ou G respectivement dans cinq et un cas et pour un cas de l’acide fusidique. Le relais etait assure majoritairement par de la penicilline M. La voie intraveineuse etait utilisee 15 jours en moyenne, la voie orale sept jours. Il n’y a eu ni deces ni sequelle dans la serie etudiee. Conclusions. – Meme si cette etude n’a pas de caractere epidemiologique exhaustif, les fasciites et cellulites apparaissent rares. La difficulte du diagnostic ne saurait expliquer une sous-estimation de la frequence. La porte d’entree la plus frequente chez l’enfant est la vesicule varicelleuse. Le site d’infection et l’utilisation d’anti-inflammatoires ne semblent pas etre des facteurs de mauvais pronostic. Les cellulites aux limites histologiques et cliniques floues sont souvent confondues avec les fasciites. Le traitement de la cellulite est la penicillinotherapie en premiere intention et ce en l’absence de recommandations consensuelles. Le traitement des fasciites necrosantes consiste en un debridement chirurgical, la precocite du geste etant essentielle.
Published: 2001
Full Text: View/download PDF

24. Inhalation treatment: Errors in application and difficulties in acceptance of the devices are frequent in wheezy infants and young children

Author: Christophe Marguet, V. Lefay, Eric Mallet, E. Jeannot, Laure Couderc, and P. Le Roux
Subjects: Pediatrics, medicine.medical_specialty, Inhalation, Treatment regimen, Crying, business.industry, Immunology, medicine.disease, Inhalation technique, El Niño, Pediatrics, Perinatology and Child Health, medicine, Immunology and Allergy, Health education, medicine.symptom, business, Asthma
Abstract: The recent availability of small-volume spacers has facilitated the general use of inhaled treatment in infants. The purpose of this study was to evaluate any errors made by parents when using this new inhalation technique and the child's behavior during the inhalation. Ninety-four young children (61% boys) under 5 years of age were enrolled in the study. Inhalation treatment was recommended either by a general practitioner or by a pediatrician. Data concerning treatment regimens, the ability of parents to use the spacer and metered-dose inhalers (MDIs), and the acceptance of the devices, were collected by means of a demonstration and questionnaire. Unexpectedly, the doses, administration times, and duration of the treatments varied from one child to the next. No explanation or training in administering the treatment via the spacers was given to 12% and 47% of the parents, respectively. Fourteen per cent of parents did not shake the MDIs, 12% did not monitor the valves, and 22% allowed too short a time for inhalation. The lack of explanation increased the occurrence of errors in manipulation of the devices. The procedure was judged to be easy to follow by 78% of the parents, but the face mask was accepted with difficulty by 22% of the children. Repeated crying during administration of the treatment was observed in 38% of the patients, particularly the youngest. Crying influenced the acceptance of the face mask, reduced parental compliance, and made the use of the devices more difficult. Errors altering the efficiency of inhalation treatment in infants are frequent. Most of these errors could be avoided by spending more time to inform the parents about correct usage. Furthermore, repeated crying during inhalation is common in young children and this problem should to be taken into consideration in the evaluation of treatment.
Published: 2001
Full Text: View/download PDF

25. Toux chronique, asthme et allergie

Author: Laure Couderc, N. Bocquel, Eric Mallet, and Christophe Marguet
Subjects: Allergy, Pediatrics, medicine.medical_specialty, Productive Cough, business.industry, Respiratory disease, medicine.disease, respiratory tract diseases, Atopy, Chronic cough, El Niño, Pediatrics, Perinatology and Child Health, Physical therapy, Medicine, medicine.symptom, business, Morning, Asthma
Abstract: The medical approach of chronic cough suffers from the lack of a standardised definition. The most frequently encountered criterion is a recurrent cough observed during several consecutive months, each episode lasting at least 1 week. The link between recurrent cough and asthma is still discussed. Cough-related asthma diagnosis is facilitated when wheezing is clearly confirmed, or may be reminded by a nonproductive middle night cough, or an exercise-triggered cough, or the presence of personal or familial atopy. Conversely, an early morning and productive cough associated with tobacco exposure do not suggest asthma.
Published: 2001
Full Text: View/download PDF

26. Réflexions sur le recrutement des universitaires en pédiatrie

Author: Pierre Cochat, Stéphane Blanche, Jacques Sarles, Eric Mallet, Marc Tardieu, A Bensman, Entz-Werlé N, Pierre Gressens, E Legall, Dalle Jh, A Labbé, J Motte, Yannick Aujard, A Clément, and A Lienhardt
Subjects: 03 medical and health sciences, Medical education, 0302 clinical medicine, Publishing, business.industry, 030225 pediatrics, Pediatrics, Perinatology and Child Health, MEDLINE, Personnel selection, business, Psychology, Faculty medical, Career choice
Published: 2010
Full Text: View/download PDF

27. Maladie de Lyme chez l'enfant en Haute-Normandie: à propos d'une enquête hospitalière

Author: M. Rouillier-Saas, E. Jeannot, Christophe Marguet, C. Forget, M. Meunier, J. Boulloche, and Eric Mallet
Subjects: medicine.medical_specialty, business.industry, medicine.drug_class, Incidence (epidemiology), Antibiotics, Amoxicillin, medicine.disease, Dermatology, Lyme disease, Pediatrics, Perinatology and Child Health, Ceftriaxone, medicine, Paralysis, Erythema migrans, medicine.symptom, business, Meningitis, medicine.drug
Published: 2000
Full Text: View/download PDF

28. Les détresses respiratoires dans les services d'accueil et d'urgences pédiatriques Epidemiologie et critères d'évaluation

Author: D. Feray, Christophe Marguet, N. Bocquel, Laure Couderc, and Eric Mallet
Subjects: Sex factors, business.industry, Pediatrics, Perinatology and Child Health, Severity of illness, Medicine, Medical emergency, Acute dyspnea, business, medicine.disease, Paediatric emergency
Abstract: The medical part of the activity in the emergency units increased and has been ascribed to the raised number of infants or children admitted for acute dyspnea. This review is based on the published reports and the experience from the paediatric emergency unit from the Rouen area with 450,000 inhabitants, in France. We put forward the known epidemiological data and discussed the available means for the practitioner, which could help him in the decision to hospitalize. This review suggests that algorithms of treatment and severity evaluations must be set up in paediatric emergency units in order to validate them and specify the children who requires hospitalisation.
Published: 2000
Full Text: View/download PDF

29. Finite element analysis of sewing process

Author: Eric Mallet and Ruxu Du
Subjects: Engineering, Polymers and Plastics, business.industry, Materials Science (miscellaneous), Process (computing), Mechanical engineering, Deformation (meteorology), General Business, Management and Accounting, Finite element method, Perpendicular, Ansys software, Business, Management and Accounting (miscellaneous), Material properties, business, Literature survey, Beam (structure)
Abstract: Sewing is one of the most commonly used manufacturing processes in the world. Millions of parts are sewn every day ranging from cloths, shoes, furniture, to automobile seat covers. However, it is also one of the least understood processes. In fact, according to literature survey, few know how to calculate the sewing force or the fabric deformation during the sewing. This paper presents our research on using finite element model (FEM) to study the sewing process. The model is developed using ANSYS software system. In the model, the fabric is approximated by a number of perpendicular beam elements with elastic and plastic capabilities. On the other hand, the needle is modeled by a simple elastic beam. The contact between the two parts is modeled by contact elements. The variations of the needle geometry and the fabric material properties as well as the sewing conditions are also included in the model. The model can simulate the needle piercing through a material, and calculates the sewing forces as well as the fabric deformation forming a hole. It has been verified experimentally and can be used to study the effects of the key sewing parameters such as the fabric material properties and the needle geometry.
Published: 1999
Full Text: View/download PDF

30. Anaphylaxie de l'enfant et de l'adolescent: à propos de 44 patients âgés de 2 mois à 15 ans

Author: Laure Couderc, Eric Mallet, C Leloet, T. Blanc, D. Feray, R Amar, and Christophe Marguet
Subjects: Gynecology, medicine.medical_specialty, Injury control, business.industry, Accident prevention, Pediatrics, Perinatology and Child Health, Medicine, Poison control, business
Abstract: Resume La frequence de l'anaphylaxie. dont les symptomes sont le choc hypovolemique et/ou l'œdeme de Quincke. augmente particulierement au cours de l'allergie alimentaire. Nous rapportons une serie de 44 enfants âges de 2 mois a 15.5 ans ayant consulte pour anaphylaxie au service d'accueil et d'urgences pediatriques. Trente-deux pour cent ont presente une hypotension, trois enfants ayant du etre admis en reanimation. Un œdeme du visage et une detresse respiratoire etaient presents respectivement dans 86 et 66 % des cas. Parmi les antecedents, 25 % avaient des œdemes ou urticaires recidivants. 31 % sont asthmatiques et 41 % allergiques. Les etiologies retrouvees sont les suivantes: 42.5 % allergies alimentaires, 14.8 % medicamenteuses (aspirine et betalactamines), 9 % sont dues a un pneumallergene, 4,2 % a une hyposensibilisation. 4.2 % a une piqure d'insecte. 6.4 % diverses. 6,4 % sont idiopathiques. Environ 12,4 % des enfants n'ont pas ete explores suffisamment sur le plan allergologique. Soixante quinze pour cent des trophallergenes identifies sont les proteines du lait de vache, l'arachide, l'œuf et le poisson. L'evolution a moyen terme montre neuf recidives, trois fois liees a des tests de provocation orale faussement negatifs. L'analyse des therapeutiques demontre une sous-utilisation de l'adrenaline malgre le caractere de gravite des symptomes.
Published: 1999
Full Text: View/download PDF

31. Pseudo-hypoparathyroïdies: nouvelles approches diagnostiques et thérapeutiques

Author: Jean-Claude Carel, J.L. Chaussain, Eric Mallet, and Michèle Garabédian
Subjects: business.industry, Pediatrics, Perinatology and Child Health, medicine, Computational biology, medicine.disease, business, Pseudohypoparathyroidism
Published: 1997
Full Text: View/download PDF

32. [Vitamin D in childhood]

Author: Michel, Vidailhet and Eric, Mallet
Subjects: Child Development, Adolescent, Child, Preschool, Drug Resistance, Nutritional Requirements, Humans, Infant, Vitamin D, Child, Vitamin D Deficiency, Nutrition Disorders, Rickets
Abstract: Infantile Nutritional Rickets has disappeared almost completely in France since 1992 as vitamin D enriched formula availability and previous vitamin D supplementation of infants. The search of evocative symptoms of rickets should be a routine procedure in infants, in particular in case of insufficient vitamin D intake i.e. breastfeeding, and the possibility of vitamin D resistant rickets. Hypocalcaemia occurs not only at the first but also the advanced stages of vitamin D deficiency, and may be responsible for severe cardiologic, neurologic or respiratory complications with possibility of infant death. For the young children between 1 and 5 years and for adolescents, vitamin D insufficiency is responsible for poor skeletal mineralization, loss of bone strength, and a reduction of peak of bone mineral mass at the end of puberty. The new Dietary Reference Intakes (DRI, 2011) increased greatly the Recommended Dietary allowances (RDA) from 200 to 600 IU/d (15 μg/d) for individuals from 1 to 70 years of age. These levels are not reached in winter, even in countries, like USA and Canada, where vitamin D milk fortification is mandatory and others like Japan and North-European countries despite high fish consumption. From 1 to 5 years of age and during adolescence, a winter vitamin D3 supplementation is necessary with 80.000 or 100.000 IU periodic loads every 3 months i.e. in November and February. In cases of an underlying risk, i.e. insufficient vitamin D photosynthesis in summertime (dark skin, wearing heavily skin-covering clothes, or several skin diseases), or digestive, renal or nutritional pathologies, use of some drugs, loading dose of 80.000 or 100.000 IU, every 3 months should be administered over the year.
Published: 2013

33. Position de sommeil, prévention de la mort subite du nourrisson et reflux gastroœsophagien

Author: Eric Mallet, M Dehan, C Faure, C. Maurage, Y Brusquet, N. Boige, Jean Navarro, Alain Dabadie, J.P. Cézard, O. de Bethmann, Frédéric Gottrand, Jacques Schmitz, J. P. Olives, P.H. Benhamou, P. Chapoy, Christophe Dupont, A Bedu, Jacques Sarles, Michel Vidailhet, Yannick Aujard, E Briand, O Mouterde, Dominique Turck, J.C. Gabilan, and B Leluyer
Subjects: Gynecology, medicine.medical_specialty, business.industry, Pediatrics, Perinatology and Child Health, Medicine, Sudden infant death syndrome, business, Sudden death
Abstract: Resume Sur la base d'etudesepidemiologiques demontrant son efficacitedans la prevention de la mort subite du nourrisson (MSN), la position dorsale ou laterale pendant le sommeil est recommandee pour tous les nourrissons en dehors de situations medicales particulieres. Le reflux gastroœsophagien (RGO) constitue une situation particuliere oula position proclive ventraleâ30° a fait la preuve de son efficacitetherapeutique. La conference de consensus considere que ce traitement positionnel du RGO ne doiteˆtre envisageque dans les circonstances oule benefice attendu apparait superieur au risque de MSN qu'il induit. La position en proclive ventral avec orthostatisme de 30° ne doit paseˆtre un traitement de premiere intention du RGO non compliquedu nourrisson et du nouveau-neaˆterme, mais elle reste un deselements du traitement dans les cas resistants aux prescriptions dietetiques et medicamenteuses.
Published: 1996
Full Text: View/download PDF

34. Infant Primary Hypothyroidism as the First Manifestation of Pseudohypoparathyroidism Type 1a

Author: Claudine Heinrichs, Nigel Loveridge, Pierre Bergmann, Noemi Perlmutter, Eric Mallet, Christian Herens, Michèle Toppet, and Henri Keutgen
Subjects: medicine.medical_specialty, Endocrinology, business.industry, Endocrinology, Diabetes and Metabolism, Internal medicine, Pediatrics, Perinatology and Child Health, Primary hypothyroidism, medicine, Pseudohypoparathyroidism Type 1a, business, medicine.disease, Pseudohypoparathyroidism
Published: 1995
Full Text: View/download PDF

35. Primary Hyperparathyroidism in Neonates and Children

Author: Mireille Castanet and Eric Mallet
Subjects: endocrine system, Pathology, medicine.medical_specialty, Pediatrics, animal structures, Cinacalcet, endocrine system diseases, business.industry, Incidence (epidemiology), Rickets, medicine.disease, humanities, Hypotonia, embryonic structures, medicine, medicine.symptom, Multiple endocrine neoplasia, business, Pseudohypoparathyroidism, Hypophosphatemia, Primary hyperparathyroidism, medicine.drug
Abstract: Objectives: Primary hyperparathyroidism (HP1) in childhood is thought to be extremely rare. Its exact incidence remains unknown, as do the characteristics of HP1. A retrospective st
Published: 2012
Full Text: View/download PDF

36. Parathormone Resistance in Children

Author: Agnès Linglart and Eric Mallet
Subjects: Pediatrics, medicine.medical_specialty, biology, business.industry, Parathyroid hormone, medicine.disease, Loss of function mutation, Hyperphosphatemia, medicine, GNAS complex locus, biology.protein, Endocrine system, Pseudopseudohypoparathyroidism, Presentation (obstetrics), business, Pseudohypoparathyroidism
Abstract: This chapter describes the spectrum of problems in children in which there is resistance to parathyroid hormone. This is described by the term pseudohypoparathyroidism. The authors describe the clinical presentation of all of the various parathyroid hormone resistant syndromes and their associated general endocrine abnormalities and skeletal changes. The known genetic abnormalities are highlighted in each of these disorders. The chapter concludes with a detailed presentation of the clinical management of all these problems.
Published: 2012
Full Text: View/download PDF

37. Immunogenicity and safety of CRM₁₉₇ conjugated 9-valent pneumococcal and meningococcal C combination vaccine in healthy infants

Author: Eric, Mallet, Elisabeth, Brachet, Philip, Fernsten, France, Laudat, Ahmad, Razmpour, and William C, Gruber
Subjects: Male, Infant, Newborn, Infant, Meningococcal Vaccines, Neisseria meningitidis, Antibodies, Bacterial, Pneumococcal Infections, Meningococcal Infections, Pneumococcal Vaccines, Streptococcus pneumoniae, Immunoglobulin G, Humans, Female, Vaccines, Combined, Serotyping
Abstract: Streptococcus pneumoniae and Neisseria meningitidis cause invasive disease in children aged2 years. While individual conjugate vaccines are available to protect this age group against these pathogens, availability of a vaccine combining these antigens into a single injection is desirable. This study randomized 467 healthy infants to receive 4 doses of combination 9-valent pneumococcal and meningococcal serogroup C conjugate vaccine (9vPnC-MnCC) or 9-valent pneumococcal conjugate vaccine (9vPnC). Percentages of subjects achieving immunoglobulin G (IgG) antibody concentrations ≥0.35μg/mL and geometric mean IgG concentrations for each pneumococcal serotype in the 9vPnC-MnCC group were noninferior compared to the 9vPnC group. Both vaccines were well-tolerated.
Published: 2010

38. Long-term prevention of allergic diseases by using protein hydrolysate formula in at-risk infants

Author: Alain Henocq and Eric Mallet
Subjects: Allergy, medicine.medical_specialty, Pediatrics, Time Factors, Protein Hydrolysates, Immunoglobulin E, Gastroenterology, Hydrolysate, Dermatitis, Atopic, Cow milk, Risk Factors, Internal medicine, medicine, Humans, Prospective Studies, Family history, biology, business.industry, Body Weight, Infant, Newborn, Caseins, medicine.disease, Body Height, Cord blood, Pediatrics, Perinatology and Child Health, biology.protein, Lower prevalence, Infant Food, Milk Hypersensitivity, business, Allergy history, Follow-Up Studies
Abstract: This prospective, long-term study assessed the effects of a protein hydrolysate formula on allergy prevention in infants with a family history of allergy. Infants were randomly assigned to receive either the hydrolysate formula (n = 92) or an adapted cow milk formula (n = 85) alone or with breast-feeding for 4 months. The groups did not differ in family allergy history scores or cord blood IgE levels. After 4 months, total IgE levels and allergic reactions did not differ significantly between groups, although the hydrolysate group had a lower prevalence of eczema. At 12 months of age, neither IgE levels nor allergic reactions were significantly different. At 2 years of age, however, 18 allergic reactions had occurred in the hydrolysate group and 31 had occurred in the control group; the differences were significant for eczema (p0.001) but not for asthma. At 4 years of age, allergic signs were found in 11 children in the hydrolysate group and in 17 children in the control group; the difference was significant only for eczema (p0.01). These results suggest that early feeding of a protein hydrolysate formula to infants at risk for allergies had a long-term preventive effect on the prevalence of eczema but not of asthma.
Published: 1992
Full Text: View/download PDF

39. GTP-Dependant Protein (Gs) Activity in Preterm Infants

Author: Claude Fessard, Ph. Brunelle, Eric Mallet, J.P. Basuyau, and C. Marguet
Subjects: Adult, medicine.medical_specialty, Hypocalcemia, GTP', Parathyroid hormone receptor, Infant, Newborn, Parathyroid hormone, Gestational Age, Biology, Pathophysiology, Endocrinology, GTP-Binding Proteins, Recien nacido, Internal medicine, Pediatrics, Perinatology and Child Health, medicine, Humans, Neonatal hypocalcemia, Dependant, Infant, Premature, Developmental Biology
Abstract: In a previous study, we showed a renal resistance to PTH in preterm infants during their 1 st week of life. We proposed it could explain early neonatal hypocalcemia. Such renal resistance is well known in type 1 pseudohypoparathyroid patients and is explained by a defect of stimulatory GTP-dependant protein (Gs). To determine if functional immaturity in the Gs protein could be involved in PTH resistance, we studied 27 newborn babies: 7 full-term and 20 preterm babies. Biological activity of the Gs unit was determined on days 1 3 and 10 after delivery by bioassay. No correlation was found between the Gs unit activity and either gestation or birth weight at these dates. Eight infants had hypocalcemia and their Gs unit activity did not differ from those with normocalcemia. Furthermore, we showed that the Gs unit is active from 29 weeks of gestation. We conclude that the Gs protein appears not to be involved in the pathophysiology of early renal resistance to PTH and therefore in early neonatal hypocalcemia.
Published: 1992
Full Text: View/download PDF

40. [Recurrent upper respiratory tract infections and otitis in children]

Author: Philippe, Reinert, Jean, Stagnara, Pascale, Roy, Eric, Mallet, and Joël, Gaudelus
Subjects: Male, Age Factors, Infant, Pharyngitis, Hypertrophy, Pacifiers, Otitis Media, Breast Feeding, Sex Factors, Recurrence, Risk Factors, Air Pollution, Child, Preschool, Adenoids, Gastroesophageal Reflux, Hypersensitivity, Humans, Female, Respiratory Tract Infections, Rhinitis
Abstract: Recurrent upper respiratory tract infections should be considered as a normal process in infants who build immune defenses in an environment where they meet viruses. Nasal lavage with saline serum and the blowing when possible are the only treatment justified in all the cases. Antibiotic treatment is not justified. It does not shorten the course and does not prevent complications. Recurrent otitis media (three episodes in six months or four in one year) are the most common complication. Bacterial superinfections are due to bacteria who colonise nasopharynx. Facilitating factors for recurrent ENT infections in children are individual: age, sex, martial deficiency, gastro-oesophageal reflux, adenoid growths. Other facilitating factors are environmental: absence or short duration of breast-feading, pollution, passive smoking, day care center. In the great majority of cases, laboratory tests are unnecessary. The most important is to reassure because recurrent upper respiratory infections improve with time. Different facilitating factors previously described have to be taken into account and should allow to decrease the number of episodes.
Published: 2007

41. Neutrophil but not eosinophil inflammation is related to the severity of a first acute epidemic bronchiolitis in young infants

Author: Christophe Marguet, Nathalie Bocquel, Jacques Benichou, Jean Pierre Basuyau, Marie France Hellot, Laure Couderc, Eric Mallet, and Bertrand Macé
Subjects: Eotaxin, Male, medicine.medical_specialty, Neutrophils, Immunology, Enzyme-Linked Immunosorbent Assay, Tachypnea, Gastroenterology, Severity of Illness Index, Hypoxemia, Disease Outbreaks, Leukocyte Count, Internal medicine, Immunopathology, Albumins, Immunology and Allergy, Medicine, Bronchiolitis, Viral, Humans, Prospective Studies, Hypoxia, Inflammation, Eosinophil cationic protein, business.industry, Respiratory disease, Interleukin-8, Sputum, Infant, Eosinophil, Length of Stay, medicine.disease, Eosinophils, medicine.anatomical_structure, Bronchiolitis, Pediatrics, Perinatology and Child Health, Acute Disease, Female, France, medicine.symptom, business, Biomarkers
Abstract: Acute bronchiolitis is the main cause of emergency visits and hospitalizations in infants. Recent data suggest that neutrophil- and eosinophil-mediated inflammations were part of bronchiolitis pathophysiology. Apart from the defined risk factors, few was known on the underlying pathophysiology, which might point out the differences observed in the severity of the disease. The aim of this study was to assess whether the clinical severity of acute epidemic bronchiolitis in young infants might be related to a specific underlying inflammatory process. Total and differential cell counts, IL-8, eotaxin, eosinophil cationic protein (ECP) and albumin levels were assessed at the time of admission in bronchial secretions from 37 infants (median age 17 wk) with acute bronchiolitis. Outcome severity variables were: hypoxemia, Silverman score, tachypnea, feeding alteration, and duration of hospitalization. Neutrophils predominated, and eosinophils were present in 54% of the infants. IL-8 levels strongly correlated with ECP and albumin levels. Albumin levels were correlated with ECP and eotaxin levels. IL-8 levels were higher in infants with hypoxemia and inversely related with SaO(2) levels. IL-8 and albumin levels significantly rose with respiratory rate, and Silverman score. IL-8, albumin and ECP levels were significantly higher in infants hospitalized >/=7 days. Furthermore, IL-8 levels were correlated with the duration of hospitalization. Neither cell counts nor eotaxin levels were related to the severity criteria studied. This study suggests that IL-8-associated airway inflammation significantly contributed to the severity of acute epidemic bronchiolitis.
Published: 2007

42. Effect of iontophoresis and penetration enhancers on transdermal absorption of metopimazine

Author: Mohamed Skiba, Frédéric Bounoure, Eric Mallet, Philippe Arnaud, Malika Skiba, and Madeleine Besnard
Subjects: Swine, Skin Absorption, Dermatology, Pharmacology, Biochemistry, chemistry.chemical_compound, Isonipecotic Acids, Spectroscopy, Fourier Transform Infrared, Stratum corneum, medicine, Animals, Molecular Biology, Isopropyl myristate, Metopimazine, Transdermal, Chromatography, Iontophoresis, Ethanol, Chemistry, Transdermal route, Penetration (firestop), Propylene Glycol, Solvent, medicine.anatomical_structure, Antiemetics, medicine.drug
Abstract: Summary Background Metopimazine is an antiemetic drug already used by oral and rectal administration. It would be interesting to develop a new formulation for a transdermal administration. Objective The objective of this study was to determine the influence of iontophoresis on the metopimazine transdermal absorption and the possible synergistic enhancement with chemical enhancers. Methods Transdermal transport of metopimazine was studied in vitro in a Franz cell with pig skin according to the following protocol: 1 h of iontophoresis followed by 7 h of passive diffusion. Different current densities were applied: 0, 0.125, 0.25 and 0.5 mA/cm 2 . Chemical enhancers used as solvent dilution were ethanol, propylene glycol and isopropyl myristate. Metopimazine was assayed by HPLC. Fourier transform infrared spectroscopy was used to determinate the interaction between chemical enhancers and stratum corneum . Results The iontophoresis has increased the percutaneous absorption of metopimazine and has decreased the lag time with 3.85 ± 0.90 μg/(cm 2 h) and 1.9 h for 0.5 mA/cm 2 and with 0.27 ± 0.20 μg/(cm 2 h) and >8 h for passive diffusion. Transdermal transport has been increased with current density and with isopropyl myristate and was not modified by ethanol or propylene glycol. Conclusion Results indicated that iontophoresis is an effective method for transdermal administration of metopimazine.
Published: 2007

43. Evaluation of a new, wireless pulse oximetry monitoring system in infants: the BBA bootee

Author: Christian Dageville, Christian Terlaud, Dominique Ronayette, Marc Lubrano, Eric Mallet, Larissa I. Netchiporouk, Yves Brusquet, Francis Klefstad-Sillonville, David Blanc, Yves Rimet, Olivier Lerda, Jean-Luc Weber, Jérôme Silve, and Caroline Rambaud
Subjects: Artifact (error), medicine.diagnostic_test, business.industry, Computer science, Beats per minute, Pulse oximetry monitoring, Accelerometer, Pulse oximetry, medicine, Wireless, business, Telecommunications, Clinical evaluation, Simulation, Electronic unit
Abstract: A new system for wireless monitoring of pulse oximetry (SpO2) was developed on the basis of a Nonin OEM III oximetry module and a radiofrequency transceiver. The electronic unit and the power supply was integrated into a specially designed infant shoe named BBA bootee. Clinical evaluation of the system revealed a good agreement between the pulse oximetry data transmitted by the BBA bootee and those recorded simultaneously by a reference monitor. The comparative data collected in 39 babies yielded a mean (bias SD) value of (−1.1 1.9)% for SpO2 and (−2 8) beats per minute for heart rate. Use of an integrated accelerometer/actimeter to reduce the motion artifact is addressed as well as ergonomics of the sensor-supporting garment.
Published: 2007
Full Text: View/download PDF

44. Primary hyperparathyroidism in neonates and childhood. The French experience (1984-2004)

Author: Eric, Mallet
Subjects: Adenoma, Male, Adolescent, Multiple Endocrine Neoplasia, Infant, Newborn, Infant, Hyperparathyroidism, Primary, Phosphates, Age Distribution, Parathyroid Neoplasms, Parathyroid Hormone, Child, Preschool, Mutation, Humans, Calcium, Female, France, Child, Receptors, Calcium-Sensing, Retrospective Studies
Abstract: Primary hyperparathyroidism (HP1) in childhood is thought to be extremely rare. Its exact incidence remains unknown, as do the characteristics of HP1. A retrospective study collection was conducted on cases supplied by members of the Working Group on Calcium Metabolism throughout France over a 20-year period (1984-2004), since the availability of the intact parathormone (iPTH) radioimmunoassay.55 cases were collected of which 11 were neonates. Among the 44 children and adolescents, there were 18 male and 26 female patients, ranging in age from 6 to 18 (mean 13) years. 83% were symptomatic and 43% had nephrolithiasis. Symptoms were associated with high serum calcium and inappropriate iPTH levels. Ultrasonography and technetium-labelled methoxyisobutylisonitrile scintigraphy are useful tools for the preoperative localization of adenomas, particularly in adolescents. Intraoperative iPTH assays are effective in minimizing invasive parathyroidectomy. All patients, except neonates, underwent surgery: 29 adenomas and 11 hyperplasias were found. Two multiple endocrine neoplasias (MENs) were subsequently discovered. Since the calcium-sensing receptor (CaSR) mutation was reported, the form of management in neonates has become more medical (intravenous diphosphonates) than surgical. On follow-up no recurrence was observed except for MEN.These national results reflect HP1 epidemiology. HP1 is a rare entity and appears to be a severe disease in terms of symptoms with regard to management. The use of molecular biology tests could be useful not only in neonatal cases (CaSR mutation) but also prior to surgery in children (MEN mutation).
Published: 2006

45. Delineating a Ca2+ binding pocket within the venus flytrap module of the human calcium-sensing receptor

Author: Christophe Petrel, Caroline Silve, Christine Leroy, Martial Ruat, Henri Bruel, Didier Rognan, Eric Mallet, Transports épithéliaux: bases structurales, modulations, modèles pathologiques, Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Claude Bernard - Physiologie et Pathologie ((IFR_2)), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire de neurobiologie cellulaire et moléculaire (NBCM), Centre National de la Recherche Scientifique (CNRS), Institut de Neurobiologie Alfred Fessard (INAF), Service de médecine néonatale, Groupe Hospitalier du Havre, Service de pédiatrie médicale et médecine de l'adolescent [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Pharmacochimie de la communication cellulaire (PCC), Université Louis Pasteur - Strasbourg I-Centre National de la Recherche Scientifique (CNRS), and Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Subjects: Male, Neonatal severe hyperparathyroidism, Class C GPCR, MESH: Amino Acid Sequence, MESH: Base Sequence, Biochemistry, 0302 clinical medicine, MESH: Animals, Receptor, MESH: Phylogeny, Phylogeny, chemistry.chemical_classification, 0303 health sciences, Autosomal-dominant hypocalcemia, Pedigree, Amino acid, MESH: Receptors, AMPA, MESH: Calcium, Metabotropic glutamate receptor 1, 7-transmembrane domain, Female, Functional expression, [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], Calcium-sensing receptor, MESH: Receptors, Calcium-Sensing, MESH: Mutation, Familial hypocalciuric hypercalcemia, MESH: Rats, MESH: Pedigree, Allosteric modulator, Biology, Metabotropic glutamate-receptor, Protein coupled receptors, 03 medical and health sciences, Animals, Humans, [SDV.BBM]Life Sciences [q-bio]/Biochemistry, Molecular Biology, Amino Acid Sequence, Receptors, AMPA, Binding site, Molecular Biology, 030304 developmental biology, G protein-coupled receptor, Binding Sites, MESH: Humans, Base Sequence, Cell Biology, Taste receptors, MESH: Male, Rats, Extracellular Ca2+-sensing receptor, chemistry, MESH: Binding Sites, Metabotropic glutamate receptor, Mutation, Calcium, Receptors, Calcium-Sensing, MESH: Female, 030217 neurology & neurosurgery
Abstract: The Ca(2+)-sensing receptor (CaSR) belongs to the class III G-protein-coupled receptors (GPCRs), which include receptors for pheromones, amino acids, sweeteners, and the neurotransmitters glutamate and gamma-aminobutyric acid (GABA). These receptors are characterized by a long extracellular amino-terminal domain called a Venus flytrap module (VFTM) containing the ligand binding pocket. To elucidate the molecular determinants implicated in Ca(2+) recognition by the CaSR VFTM, we developed a homology model of the human CaSR VFTM from the x-ray structure of the metabotropic glutamate receptor type 1 (mGluR1), and a phylogenetic analysis of 14 class III GPCR VFTMs. We identified critical amino acids delineating a Ca(2+) binding pocket predicted to be adjacent to, but distinct from, a cavity reminiscent of the binding site described for amino acids in mGluRs, GABA-B receptor, and GPRC6a. Most interestingly, these Ca(2+)-contacting residues are well conserved within class III GPCR VFTMs. Our model was validated by mutational and functional analysis, including the characterization of activating and inactivating mutations affecting a single amino acid, Glu-297, located within the proposed Ca(2+) binding pocket of the CaSR and associated with autosomal dominant hypocalcemia and familial hypocalciuric hypercalcemia, respectively, genetic diseases characterized by perturbations in Ca(2+) homeostasis. Altogether, these data define a Ca(2+) binding pocket within the CaSR VFTM that may be conserved in several other class III GPCRs, thereby providing a molecular basis for extracellular Ca(2+) sensing by these receptors.
Published: 2005
Full Text: View/download PDF

46. Mutation spectrum of human SLC39A4 in a panel of patients with acrodermatitis enteropathica

Author: Sébastien, Küry, Monia, Kharfi, Ridha, Kamoun, Alain, Taïeb, Eric, Mallet, Jean-Jacques, Baudon, Catherine, Glastre, Bruno, Michel, Francis, Sebag, David, Brooks, Volker, Schuster, Catherine, Scoul, Brigitte, Dréno, Stéphane, Bézieau, and Jean-Paul, Moisan
Subjects: Male, Intestinal Diseases, Zinc, Acrodermatitis, DNA Mutational Analysis, Mutation, Humans, Female, RNA, Messenger, Cation Transport Proteins, Pedigree, Protein Structure, Tertiary
Abstract: Acrodermatitis enteropathica is rare autosomal recessive disorder characterized by a severe nutritional zinc deficiency. We and others have recently identified the human gene encoding an intestinal zinc transporter of the ZIP family, SLC39A4, as the mutated gene in acrodermatitis enteropathica (AE). A first mutation screening in 8 AE families (15 patients out of 36 individuals) revealed the presence of six different mutations described elsewhere. Based on these results, we have evaluated the involvement of SLC39A4 in 14 patients of 12 additional AE pedigees coming either from France, Tunisia, Austria or Lithuania. A total of 7 SLC39A4 mutations were identified (1 deletion, 2 nonsense, 2 missense, and 2 modifications of splice site), of which 4 are novel: a homozygous nonsense mutation in 3 consanguineous Tunisian families [c.143TG (p.Leu48X)], a heterozygous nonsense mutation (c.1203GA (p.Trp401X)) in a compound heterozygote from Austria also exhibiting an already known missense mutation, and distinct homozygous mutations in families from France or Tunisia [c.475-2AG and c.184TC (p.Cys62Arg)]. Furthermore, two other potential mutations [c.850GA (p.Glu284Lys) and c.193-113TC] were also observed at homozygous state in a French family formerly described. This study brings to 21 the number of reported SLC39A4 mutations in AE families.
Published: 2003

47. AFPA CO-04 - Statut de la vitamine D chez les enfants de 6 à 10 ans en France. Etude multicentrique, nationale chez 326 enfants

Author: J. Stagnara, Joël Gaudelus, Eric Mallet, and Philippe Reinert
Subjects: Pediatrics, Perinatology and Child Health
Abstract: L’etude s’est deroulee sur deux hivers d’ensoleillement different dans 22 centres. 360 enfants âges de 6 a 10 ans devaient etre inclus en fin de periode hivernale et les dosages realises sur reliquats biologiques. 326 enfants ont eu un dosage centralise de 25-OH-D nmol/L ; 38 % avaient eu une supplementation vitaminique D depuis la rentree scolaire. 3,1% etaient carences ( 100 sans consequence sur la calcemie et la calciurie. Une difference nord/sud est observee. Dans la population non supplementee (n=188), 5,3 % etaient carences, 45,2 % en situation d’insuffisance. Dans la population supplementee (n=119), aucune carence n’a ete constatee. Chez les enfants non supplementes la moitie (50,5 %) etait au moins en situation d’insuffisance en fin d’hiver. Ces resultats plaident en faveur d’une supplementation hivernale chez les 6 a 10 ans.
Published: 2014
Full Text: View/download PDF

48. P463 - Premier cas d’endocardite à Moraxella caprae

Author: Marion Caseris, I. Michelet, Ludovic Lemée, Christophe Marguet, G. Pinto Cardoso, I. Durand, and Eric Mallet
Subjects: Pediatrics, Perinatology and Child Health
Abstract: Nous rapportons le premier cas decrit d’infection humaine a Moraxella Caprae chez un enfant de 8 ans hospitalise pour fievre persistante. Dans ses antecedents, on note une cardiopathie complexe avec materiel prothetique et une rosacee oculaire traitee par corticoides locaux depuis 6 mois. On retrouve un souffle systolique connu, une splenomegalie, un discret erytheme palmaire, et des chalazions bilateraux. Sur le plan biologique, la CRP est a 100 mg/l sans hyperleucocytose. Deux hemocultures sont positives a Moraxella multisensible motivant la mise en route d’une antibiotherapie par C3G et aminoside. L’echographie cardiaque ne retrouve pas de vegetation. Les explorations a la recherche d’une porte d’entree infectieuse sont negatives. Par PCR, on identifie un Moraxella Caprae, germe commensal de l’oropharynx de la chevre. L’interrogatoire retrouve une eventuelle contamination par l’intermediaire du pere de l’enfant ayant travaille au contact de chevres. Dans la litterature, il existe des endocardites a Moraxella Lacunata avec une porte d’entree oculaire. Appartenant a la meme classification, nous ne pouvons exclure la contamination a partir des chalazions. L’evolution cardiaque et infectieuse est favorable apres une antibiotherapie prolongee de 6 semaines.
Published: 2010
Full Text: View/download PDF

49. P487 - Gravité de la grippe A H1N1 en Haute Normandie

Author: M. Mathé, Eric Mallet, S. Rigal, C. Chollat, F. Louillet, Christophe Marguet, and I. Michelet
Subjects: Pediatrics, Perinatology and Child Health
Abstract: Objectifs Evaluer la gravite de l’epidemie de grippe A H1N1 (GA) en pediatrie. Materiels et Methodes Etude descriptive, prospective, epidemiologique conduite du 1/10/2009 au 1/02/2010 au CHU de Rouen (zone d’influence environ 800000 habitants). Criteres d’inclusion : Enfants âges de 0 a 16 ans hospitalises et ayant contracte la GA. Les PCR ont ete realisees selon les criteres emis par le HCSP. Analyse de la demographie, de la morbi-mortalite et de la symptomatologie de l’echantillon. Resultats 93 enfants (âge moyen 4 ans, sex ratio H/F : 1,5) ont ete hospitalises sur 1638 syndromes grippaux admis aux urgences pediatriques (soit 5,7 %). La duree d’hospitalisation moyenne est de 2,5 jours. L’expression clinique est diverse: syndrome grippal traditionnel (fievre elevee > 39 °C (41,3 %), fievre moderee Conclusion Aspect polymorphe et peu severe de la GA. Aucun SDRA n’est a deplorer.
Published: 2010
Full Text: View/download PDF

50. Évaluation de la masse osseuse chez l’enfant : modalités, perspectives

Author: Eric Mallet, C. Cellier, and E. Blondiaux
Subjects: Gynecology, medicine.medical_specialty, business.industry, Pediatrics, Perinatology and Child Health, Osteoporosis, medicine, Mineralization (soil science), business, medicine.disease, Bone mass
Published: 2009
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Database

Publisher

93 results on '"Eric Mallet"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources